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The work presented in this thesis is a summary of my five years fellowship from 
February 2001 to February 2006 at the Division of Molecular Microbiology and 
Development of Genetic Diagnostics at the Children's Cancer Research Institute 
in Vienna, Austria under the supervision of Prof. Thomas Lion. 
The focus of my work is on the development of molecular diagnosis  
of invasive fungal disease in immunocompromised patients. Together  
with Mag. Sandra Preuner and Mag. Christine Landlinger I have established 
three DNA-based detection assays for the detection and identification of a large 
number of the clinically relevant fungal species.  
The development of the methods as outlined would not been possible 
without the contribution of Prof. Birgit Willinger and Assoc. Prof. Dr. Vladimír 
Buchta, who cultivated and donated a number of various common and rare 
fungal cultures and clinical probes for the laboratory testing.  
At times it was trying, Thomas! To you, I offer my sincerest thanks and 
gratitude for allowing me the opportunity to partake in your research group. Your 
expertise, patience, endless support and, above all, your understanding was very 
much appreciated. How you motivated and stimulated our intellectual capacity is 
worthy of strong praise. I am sorry my time with the team has come to an end. 
I would like to thank all the above mentioned colleagues whose help  
with the development and evaluation of the molecular detection assays as well  
as with the data collection and their assessment has made the completion of my 
studies possible. 
I must mention my mentors, to Ass. Prof. Jaroslav Cerman and  
Assoc. Prof. Pavel Živný. I thank you both for your time and patience, your 
scientific consultations were invaluable. 
Finally, I must say a special thanks to my family. Without your boundless 
patience, tolerance and help, Pavel, I would have never been able to finish this 
work. Vojta, Viola, thanks a lot for your love and the inspiration you gave me 
each and every day. Mum, dad, this all is because of you… 
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Molekulární detekce invazivních mykotických onemocnění  
u imunokompromitovaných pacientů 
 
V dizertační práci se mi podařilo vyvinout tři PCR metody pro kvantitativní detekci 
a identifikaci kvasinkové a plísňové DNA. Dvě metody založené na kvantifikaci  
v reálném čase s názvem PanAC PCR a “panfungal” PCR byly navrhnuty tak, 
aby detekovaly a kvantifikovaly široké spektrum plísní a kvasinek způsobujících 
invazivní mykotická onemocnění. Význam metod pro klinické využití byl v rámci 
standardizace testován retrospektivně na souborech pacientů s již 
dokumentovanými invazivními mykózami a dále pak prospektivně na souborech 
pacientů s vysokým rizikem invazivní mykózy.  
 Vzhledem k významu přesné identifikace původce onemocnění byla 
vyvinuta “semi-nested” PCR s fluorescenční detekcí pomocí kapilární 
elektroforézy umožňující rychlou identifikaci plísně či kvasinky v klinickém 
materiálu, který byl pozitivní v jedné ze širokospektrých screeningových PCR. 
Možnost klinického využití této metody byla taktéž testována na populaci 





Molecular detection of invasive fungal disease in immunocompromised 
patients 
 
In my work I have been able to establish three different PCR-based assays  
for the quantitative detection and identification of fungal DNA. Two DNA-based 
detection assays termed PanAC PCR and panfungal PCR based on the real-time 
quantitative (RQ-PCR) technology were designed to detect and quantify the most 
important fungal genera currently associated with IFD including a large number  
of pathogenic moulds and yeasts. Upon standardization of both RQ-PCR 
techniques, the applicability in the clinical setting was assessed by investigating  
a series of clinical specimens from patients with documented fungal infection, 
and by prospectively studying patient cohorts at high risk of IFD.  
In view of the importance of precise identification of the causative fungal 
pathogen, a semi-nested PCR method coupled with fluorescent capillary 
electrophoresis detection was established. It facilitates rapid identification  
of fungal species in clinical materials that test positive for IFD using one  
of the broad-range screening assays. This method was also tested  






A   Adenine 
AB   Applied Biosystems 
Ab   Antibody 
Ag   Antigene 
AIDS   Acquired immunodeficiency syndrome 
ALP   Alkaline proteinase gene 
Asp   Aspergillus 
ATCC   American Type Culture Collection 
BAL   Bronchoalveolar lavage 
BDG   1,3-β-D-glucan 
BLAST  Basic Local Alignment Search Tool 
bp   Base pair(s) 
C   Cytosine 
Can   Candida 
Cdc2   Cell-division-cycle molecule 2 
cDNA   Copy deoxyribonucleic acid 
CFU   Colony forming unit 
CI   Confidence interval 
CLSI   Clinical and Laboratory Standards Institute 
CNS   Central nervous system 
CT   Threshold cycle  
Cu-ZnSOD  Copper-zinc superoxide dismutase 
dATP   Deoxyadenosine triphosphate 
dCTP   Deoxycytidine triphosphate 
dGTP   Deoxyguanosine triphosphate 
DMSO  Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
dNTPs Deoxynucleotide triphosphates 
dsDNA Double stranded deoxyribonucleic acid 
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DSM German Collection of Microorganisms 
dTTP Deoxythymidine triphosphate 
dUTP Deoxyuridine triphosphate 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
EORTC The European Organization for Research and Treatment  
of Cancer 
EUCAST The European Committee on Antimicrobial Susceptibility 
Testing 
FAM   Fluorescein amidite (6-carboxyfluorescein) 
FDA   Food and Drug Administration 
FMCU   Faculty of Medicine, Charles University 
Fw   Forward 
G   Guanine 
gDNA   Genomic DNA 
GM   Galactomannan 
gp43   43 kDa glycoprotein 
HR-CT  High resolution computed tomography 
IA   Invasive aspergillosis  
IC   Invasive candidiasis 
IFD   Invasive fungal disease 
IFI   Invasive fungal infection 
IFICG Invasive Fungal Infections Cooperative Group 
IGS Intergenic spacer 
IHMM Institute of Hygiene and Medical Microbiology 
ITS1 Internal transcribed spacers 1 
ITS2 Internal transcribed spacers 2 
KOH Potassium hydroxide 
LLB Lyticase lysis buffer 
LNA Locked nucleic acid 
LSU Large subunit 
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MALDI-TOF MS Matrix-assisted laser desorption/ionization time of flight mass 
spectrometry 
MgCl2   Magnesium chloride 
MSG   Mycoses Study Group 
NaCl   Sodium chloride 
NASBA  Nucleic acid sequence-based amplification 
NCBI   National Center for Biotechnology Information 
Pan-AC  Pan-Aspergillus -Candida assay 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
PCR-ELISA Polymerase chain reaction with enzyme-linked 
immunosorbent assay detection 
pH   Measure of the activity of the (solvated) hydrogen ion 
R   Guanine or adenine 
rDNA   Ribosomal deoxyribonucleic acid gene 
Rev   Reverse 
RFLP   Restriction fragment length polymorphism 
RFUs   Reference fluorescence units 
ROX   6-carboxyl-X-rhodamine 
RPMI   Roswell Park Memorial Institute medium 
RQ-PCR  Real-time quantitative polymerase chain reaction 
rRNA   Ribosomal ribonucleic acid gene part 
SAP(s)  Secreted aspartic proteinase gene(s) 
SSU   Small subunit 
T   Thymine 
TAMRA  6-carboxytetramethylrhodamine 
Tm   Melting temperature 
Tris   Tris(hydroxymethyl)aminomethane 
UNG   Uracil N´-glycosylase 
∆Rn   Fluorescence intensity of the reporter 





Invasive fungal diseases (IFDs) have become an increasingly common  
life-threatening complication in a variety of critically ill patients resulting in high 
mortality rates. The changes in treatment strategies, particularly  
the implementation of fungal prophylaxis in high-risk patients, have resulted  
in remarkable changes in the spectrum of fungal pathogens causing IFDs. Yeast 
infections have shifted towards a higher proportion of non-albicans Candida 
species but their overall incidence has remained stable. In contrast, IFDs caused 
by moulds including particularly various species of Aspergillus, Fusarium and 
Mucorales have increased in number. Current diagnostics of IFD is based 
primarily on conventional approaches such as microscopy, cultivation, 
histopathological examination and imaging methods which still represent the gold 
standard. The diagnosis, however, remains difficult because of the limited 
sensitivity and specificity of these methods. The detection of surrogate 
serological markers such as the fungal cell wall components galactomannan and 
(1,3)-β-D-glucan by commercially available diagnostic kits has become 
increasingly important and widely used, but the clinical interpretation  
of the results still remains controversial.  
 Rational and timely initiation of adequate antifungal treatment is  
of paramount prognostic importance, but the lack of sufficiently rapid and reliable 
diagnostics is a major impediment. In the clinical setting, the onset of antimycotic 
treatment is therefore generally based on indirect evidence for systemic fungal 
infections: i.e. clinical signs of sepsis unresponsive to different antibacterial 
agents for greater than 72-96 hours. This strategy, however, may lead  
to a significant and possibly deleterious delay of antimycotic therapy in patients 
with IFD. On the other hand, the pronounced organ toxicity of some antimycotic 
drugs provides a strong argument against prophylactic application of antifungal 
agents. Initiation of systemic antimycotic treatment based merely on clinical 
suspicion results in an unnecessary increase of organ toxicity and costs  
in instances in which no IFD is present. It is of great interest therefore to establish 
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ways of managing antimycotic treatment based on firm evidence. To address this 
task, it is necessary to employ diagnostic approaches permitting rapid, sensitive 
and specific detection of IFDs. This would allow timely initiation of treatment, 
which is crucial for favorable outcome. Moreover, the possibility of identifying the 
causing fungal pathogen would greatly contribute to optimal therapeutic 
decisions.  
Recently, a plethora of PCR-based diagnostic methods targeting different 
gene regions and exploiting a variety of amplicon detection tools was published 
and demonstrated the possibility to overcome the limitations of other diagnostic 
approaches. However, the current lack of methodological standardization and 
validation has precluded clear interpretation of the results and prevented broad 
application of PCR-based fungal diagnostics in the clinical setting. 
The present work addresses the current dilemma in molecular diagnostics 
of IFD: two DNA-based detection assays termed PanAC PCR (see chapter 2.1) 
and panfungal PCR (see chapter 2.2) based on the real-time quantitative  
(RQ-PCR) technology have been established. The PanAC assay was designed 
to detect and quantify the most important fungal genera currently associated  
with IFD including a large number of pathogenic Candida and Aspergillus species 
in a single reaction. The panfungal assay was developed to cover essentially all 
clinically relevant fungal species in two different reactions, one focusing primarily 
on moulds and the other on yeasts and Zygomycetes. More specifically,  
the spectrum of human pathogenic fungi covered by these assays includes all 
important Aspergillus and Candida species, as well as other yeasts and moulds 
of potential clinical relevance, such as Trichosporon, Cryptococcus, Fusarium, 
Mucor or Rhizopus species, and even extremely rare pathogens such  
as Saccharomyces cerevisiae and Malassezia furfur. The conceptual design  
of the RQ-PCR assays presented in this work has significantly extended  
the capacity of RQ-PCR approaches existing at the time of publication  
by facilitating the detection of more than 16 (PanAC assay) and >80 (panfungal 
assay) different pathogenic fungal species, respectively. Upon standardization  
of both RQ-PCR techniques, the applicability in the clinical setting was assessed 
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by investigating a series of clinical specimens from patients with documented 
fungal infection, and by prospectively studying patient cohorts at high risk of IFD 
(see chapters 2.1 and 2.2).  
Moreover, in view of the importance of precise identification  
of the causative fungal pathogen, a semi-nested PCR method coupled  
with fluorescent capillary electrophoresis detection was established (see chapter 
2.3). It facilitates rapid identification of fungal species in clinical materials that test 
positive for IFD using one of the broad-range screening assays. This method was 
also tested in a population of patients with documented fungal infections  
to assess its clinical potential (see chapter 2.3).  
The entire work outlined above was published in four scientific papers 
which constitute the backbone of the doctoral thesis presented. Three of the 
papers focus on the respective methodologies and their clinical application, and 
one reviews the current status of molecular diagnostics in IFD. The thesis is 
divided into three sections with overlapping description of methodological aspects 
(e.g. fungal DNA extraction procedures from various types of clinical specimens 
or fungal strains employed in testing), but the specific methodologies and results 
of clinical analysis are described and discussed in individual sections. 
It should be pointed out that the novel molecular diagnostic assays including the 
panAC and the panfungal PCR method have been patented  
(No. 06817468.9– Europe) prior to publication, and negotiations with potential 





Invasive fungal diseases (IFDs) continue to represent a significant problem  
in a large proportion of critically ill patients, particularly in individuals  
with impaired immunity. Prolonged episodes of profound neutropenia represent  
a high-risk constellation primarily in patients with hematologic malignancies 
(Michallet and Ito 2009), recipients of allogeneic bone marrow (Badley et al. 
2001), peripheral hematopoietic stem cells (Marr 2010) or solid organ transplants 
(Person et al. 2010). Moreover, AIDS patients (Hage et al. 2002) or individuals 
with other acquired immunodeficiency conditions (Pappas 2010), intensive care 
patients (Smith and Kaufmann 2010), preterm neonates (Kaufman 2007) and 
patients undergoing long-term corticosteroid therapy (Lionakis and Kontoyiannis 
2003) also carry a high risk of IFD. In addition to the state of immunosuppression, 
long-term exposure to broad spectrum antibiotic therapy, high-dose anticancer 
chemotherapy, long presence of indwelling catheters, and biological factors such 
as iron overload and patient age (Erjavec et al. 2009; Miceli et al. 2006) have 
also been shown to increase the risk of developing IFD. Furthermore, recently 
recognized genetic factors predisposing to IFD, such as impaired  
NADPH-oxidase activity (Segal and Romani 2009), disturbed production of tumor 
necrosis factor α or interleukin-10 (Sainz et al. 2007a,b) and genetic 
polymorphisms in Toll-like receptors that result in deficient production of some 
inflammatory cytokines (Bochud et al. 2008) represent conditions constituting  
a group of vulnerable patients at high risk for IFD. 
The morbidity and mortality of IFD generally depend on the causative 
pathogen, geographical location and underlying patient condition. Since  
the symptoms of IFD are often non-specific, fungal pathogens are not identified 
as causative agents in many instances or the diagnosis is established late  
in the course of infection. This contributes to high overall mortality rates ranging 
between about 30-80% (Lass-Flörl 2009), and even exceeding 90% with central 
nervous system involvement and dissemination (Walsh et al. 2008). Although  
the vast majority of these life-threatening infections are still attributable  
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to Candida and Aspergillus species, shifts in epidemiology have been noted  
with the adoption of antifungal prophylaxis resulting in the increasing occurrence 
of resistant species or the emergence of previously rare fungal species displaying 
inherent resistance to antifungal agents used in the prophylactic setting (Preuner 
and Lion 2009). Recent studies indicate a slight decrease of IFDs due to Candida 
albicans, while the incidence of non-albicans Candida infections, including those 
with reduced antifungal susceptibility (e.g. azole- and/or echinocandin-resistant 
C. glabrata, C. krusei, C. parapsilosis and C. albicans) is rising (Michallet and Ito 
2009; Lass-Flörl 2009). In addition, invasive aspergillosis (IA) has surpassed 
invasive candidiasis (IC) as the most common IFD encountered in the peripheral 
hematopoietic stem cells transplant population (Person et al. 2010). Although  
A. fumigatus continues to be the most common cause of IA, non-fumigatus 
Aspergillus species occur with increasing frequency. Of particular relevance is  
A. terreus which is associated with amphothericin B resistance and higher 
mortality (Lass-Flörl 2009). A similar spectrum of fungal pathogens is also 
observed in pediatric patients but with different frequency and mortality rates. 
The incidence of IC is higher in children than in adults (47 vs. 30/100,000 
admissions) with a mortality rate of 10%, whereas the frequency rates of IA are 
similar in children and adults, with mortality rates between 30 and 50% 
depending on the underlying disease (Dornbusch et al. 2009). Beside IFDs 
caused by Aspergillus and Candida species, hitherto rarely observed fungal 
genera associated with very high fatality are becoming more common (Lass-Flörl 
2009; Richardson and Lass-Flörl 2008). These include hyalohyphomycetes such 
as Fusarium and Scedosporium, phaeohyphomycetes (darkly-pigmented  
or dematiaceous fungi), basidiomycetous yeasts (Cryptococcus, Trichosporon, 
Malassezia), and, very importantly, different members of the Mucorales, namely 
Rhizopus and Mucor. IFDs are often difficult to diagnose, but early detection  
of the causative pathogen is an essential prerequisite for timely onset  
of appropriate antifungal therapy and favorable outcome. Therefore,  
the development of rapid and reliable methods for early diagnosis of IFDs is 
urgently required to improve clinical management of the disease. 
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1.1 Conventional diagnostic tests 
 
Current conventional diagnostic methods for IFDs are based on microbiological 
examination and imaging techniques. In general, microscopy, cultivation and 
most serological tests show inadequate sensitivity or specificity, and are often not 
fast enough to permit rational and timely initiation of treatment. Combination  




1.1.1 Microbiological examination 
 
Microscopy-assisted examination of microbiological samples or histological 
material enables the detection of fungal structures only when their abundance  
in the sample is high. In addition, positivity in biopsy samples is usually 
associated with an advanced stage of fungal infection (Cuenca-Estrella et al. 
2011). Histopathological examination of targeted biopsies of suspicious lesions 
identified by imaging methods provides an important improvement  
in the diagnosis of IFD, but is frequently hampered by the risk of bleeding 
complications in patients with severe thrombocytopenia (Denning 1998). Another 
way how to increase sensitivity of microscopical examination is using fluorescent 
dyes (e.g., calcofluor) which are specifically binding to components of fungal cell 
wall, including Pneumocystis jiroveci. In case of histopathological sections 
immunohistochemical techniques can be useful in discrimination among fungal 
pathogens, e.g. Aspergillus spp. from other filamentous fungi such as Fusarium 
or Scedosporium (Choi et al. 2004; Kaufman et al. 1997; Verweij et al. 1996). 
Mycological cultivation of various biological specimens including peripheral 
blood has been routinely employed for the detection of clinically relevant fungal 
pathogens. However, blood cultures were described to fail in approximately 50% 
of infections reported in patients with IC detected at autopsy (Pemán et al. 2011). 
In addition, aspergilli and other moulds are rarely diagnosed from blood cultures 
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with exceptions such as Fusarium species. Negative findings therefore cannot 





Identification of clinically relevant fungi at the species or genus levels plays  
an increasingly important role as the spectrum of human pathogenic fungi 
broadens. It can provide additional important information on the causative agent 
and the nature of infection especially in terms of its course, intensity, organ 
predilection, and response to antifungal treatment. Owing to the relatively small 
discriminatory value of morphological features, yeast identification is based  
on biochemical tests which are available as a commercial kits (e.g., API 20C, ID 
32C, BioMériéux) or automated devices (e.g., VITEK, BioMériéux). Special 
methods for identification of C. albicans and some other frequent Candida 
species have been utilized in mycological laboratories such as germ tube test, 
induction of chlamydospore formation on rice agar, or cultivation on chromogenic 
media (Pincus 2007). Methods for mould identification often rely  
on morphological description of a fungus based on colony appearance and 
microscopic picture. They are time-consuming and require experienced 
laboratory workers. 
Apart from conventional techniques, more precise and rapid identification 
of yeasts as well as moulds is enabled by molecular analysis. Nucleic acid-based 
methods, including sequencing, and the establishment of protein profile  
by matrix-assisted laser desorption/ionization time of flight mass spectrometry 
(MALDI-TOF MS) can be used now (see section 1.2.2.1). 
 
 
1.1.3 Antifungal susceptibility testing 
 
Standardized methods for antifungal susceptibility testing of yeasts and moulds 
approved by Clinical and Laboratory Standards Institute (CLSI) and The 
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European Committee on Antimicrobial Susceptibility Testing (EUCAST) are 
available in the formats of agar diffusion and broth dilution (Lass-Flörl et al. 
2010). Interpretative breakpoints have been developed for almost all clinically 
relevant systemic antifungal drugs (Pfaller et al. 2011a,b). Even when prediction 
of clinical outcome on the basis of laboratory data has not yet been optimal, 
these breakpoints represent a considerable improvement in the rational 
management of IFDs (Lass-Flörl et al. 2011; Pfaller 2012). Present effort has 
been focusing on more precise species-dependent definition of these 




1.1.4 Imaging methods 
 
Imaging methods play an important role in the diagnosis of IFDs.  
The radiographic features of IA are often non-specific and appear late  
in the course of disease. High-resolution computed tomography and magnetic 
resonance imaging scans make it possible to detect both pulmonary and 
extrapulmonary IA and other IFDs with a relatively high degree of probability, but 
they require the existence of macroscopic lesions, which are usually markers  
of poor prognosis (Cuenca-Estrella et al. 2011).  
 
Despite the relatively poor reliability of the methods indicated above,  
the European Organization for Research and Treatment of Cancer/Invasive 
Fungal Infections Cooperative Group (EORTC/IFICG), the National Institute  
of Allergy and Infectious Diseases Mycoses Study Group (MSG) recommend  
the indicated conventional diagnostic tests as gold standard for the definitions  




1.2 Culture-independent diagnostic tests 
 
Among the many challenges in dealing with IFDs, early diagnosis is of paramount 
importance. The negative impact of delay in the initiation of adequate antifungal 
therapy on the outcome of patients with IFDs has become evident (Michallet and 
Ito 2009; Marr 2010). There have been great efforts therefore to develop new 
surrogate markers for diagnosis of IFD including improved non-culture methods 
such as non-invasive, more sensitive and faster techniques for detection  




1.2.1 Detection of fungal antigens  
 
 
1.2.1.1 Aspergillus galactomannan  
 
Galactomannan (GM) is a polysaccharide component of the cell wall  
of Aspergillus spp. that is released by the fungus into the blood stream during 
hyphal growth. Detection and quantification of this fungal component is 
considered to be a test specific for the diagnosis of IA (De Pauw et al. 2008). 
However, other filamentous fungi such as Penicillium spp. and Paecilomyces 
spp. contain lower, yet readily detectable GM amounts in their cell wall, thus 
leading to false-positive test results with regard to IA (Cuenca-Estrella et al. 
2011). The GM sandwich Enzyme-linked immunosorbent assay (ELISA) (Platelia 
Aspergillus EIA, BioRad, USA) is the most commonly used commercially 
available test system approved for clinical screening by the Food and Drug 
Administration (FDA). Antigen determination by this test can be performed  
in serum, plasma, bronchoalveolar lavage fluid, cerebrospinal fluid and other 
body liquids. The sensitivity and specificity of the GM assay in range of 80%  
to 100% for IA varies significantly depending on the patient group, host factors, 
nutrition of the patient, administration of certain drugs and, most importantly,  
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on the threshold for GM positivity used (Wheat 2007; Einsele and Loeffler 2008). 
Based on practical experience and clinical study results, the cut-off value  
of galactomannan index was lowered from 1.5 (original manufacturer 
recommendation) to 0.5 for hemato-oncological patients, which has been 
associated with adequate sensitivity and specificity (Leeflang et al. 2008; 
Maertens et al. 2007; Meersseman et al. 2008). However, this issue is still 
controversial, and other cut-off values have been advocated (Herbrecht et al. 
2002; Lai et al. 2007). The GM assay provides best results in hematologic 
malignancies and hematopoietic stem cells transplant recipients usually  
with good sensitivity and specificity, but the test has appeared less useful  
in children, solid organ transplant recipients and other immunocompromised 
patients (Herbrecht et al. 2002; Pappas 2010).  
One of the most important limitations of the Platelia GM assay is  
the occurrence of false-positive results described in patients receiving certain  
β-lactam antibiotics such as piperacillin-tazobactam (Viscoli et al. 2004)  
or amoxicillin-clavulanate (Zandijk et al. 2008). Other possible sources  
of false-positive results are immunosuppressive drugs, namely 
cyclophosphamide (Cuenca-Estrella et al. 2011) or intravenous Plasma-Lyte® 
electrolyte solutions (Racil et al. 2007), dietary GM in pasta, cereals and formula 
milk, and cross reactivity with lipoteichoic acid of Bifidobacteria of the infantile gut 
microbiota (Dornbusch et al. 2009). 
 
 
1.2.1.2 Candida mannan and anti-mannan antibodies 
 
Mannan is released during IC and it can be detected by immunoassay tests  
with variable sensitivity (25%-85%) and a relatively satisfactory specifity (>80%). 
Serial samples are needed to overcome problems with rapid clearance  
of circulating mannan from sera and with the formation of antigen-antibody 
complexes. To get optimal diagnostic results the combination of tests  
for detection of mannan and anti-mannan antibodies should be considered 
(Prella et al. 2005; Alam et al. 2007). Alternative to Candida antigen and/or 
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antibody is the establishment of metabolic products of the yeast such as enolase 
or D-arabinitol/creatine ratio (Walsh et al. 1991; Walsh et al. 1995; Mitsutake  
et al. 1996; Yeo et al. 2006). An additional possibility is the detection  
of β-1,3-D-glucan, another cell wall component present in many fungi including 
Candida spp. although it is not immunogenic (see section 1.2.1.4). Promising 
results were provided by a study which combined β-1,3-D-glucan detection  
with antibodies against C. albicans germ tubes with sensitivity and specificity 
approaching 100% (Pazas et al. 2006). 
 
 
1.2.1.3 Cryptococcus capsular antigen 
 
Detection of the capsular polysaccharide antigen of Cryptococcus neoformans 
has an important place in diagnosis of meningitis and disseminated infections 
caused by this encapsulated yeast. There are commercial tests targeted  
to capsular glucuronoxylomannan, the main component of the antigen. Latex 
agglutination-based tests provide modestly sensitive results. Immunoassays 
(e.g., ELISA) are more reliable, especially in HIV patients (Yeo and Wong 2002; 
Antinori et al. 2005). 
 
 
1.2.1.4 Panfungal β-D-glucan  
 
An additional FDA-approved antigenemia ELISA assay detects  
the polysaccharide 1,3-β-D-glucan (BDG) which is, in contrast to galactomannan, 
present in the cell wall of most pathogenic fungi including Candida, Aspergillus, 
Fusarium, Trichosporon, Saccharomyces and Acremonium (Alexander 2002), 
thereby permitting broader detection of fungal pathogens. Notable exceptions 
include Mucorales and Cryptococcus which contain very low quantities of BDG  
in their cell walls (Cuenca-Estrella et al. 2011). However, some studies have 
recently described the utility of the test even for the detection of cryptococcosis 
and zygomycosis (Obayashi et al. 2008; Koo et al. 2009). The most frequently 
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used commercial assays for BDG detection are the Fungitell® (Associates  
of Cape Cod, USA) and Fungitec (Seikagaku) and there is no considerable 
difference in the accuracy of test results for the diagnosis of IFDs in patients  
with hematological malignancies (Lamoth et al. 2012). Although BDG methods 
appear to detect a broader range of fungal pathogens causing IFDs, none  
of these tests provide the possibility to identify the species involved. BDG 
detection in general provides good sensitivity and specificity in the range  
of 70% - 100% and 75% to 90%, respectively, including also neonatal patient 
populations (Kohno et al. 1993; Odabasi et al. 2004; Ostrosky-Zeichner L et al. 
2005; Pazos et al. 2005; Couto et al. 2007; Lu et al. 2011; Mackay et al. 2011). 
Diagnostic relevance can be improved with two consecutively positive test results 
(Odabasi et al. 2004; Lamoth et al. 2012; Onishi et al. 2012).  
However, like GM testing, BDG detection is also influenced by a number 
of factors interfering with the results and their interpretation. False-positive results 
are related to the administration of certain antimicrobials such as cefepime, 
colistin, ertapenem, cefotaxime and amoxicillin clavulanate (Marty et al. 2006). 
Additionally, some bacteria (e.g. pneumococci, Alcaligenes faecalis, 
Pseudomonas aeruginosa etc.) and exposure to BDG-containing materials such 
as cellulose filters or membranes for hemodialysis as well as immunoglobulin, 
albumin and other blood products have been documented as a source  
of false-positive results of BDG tests (Pickering et al. 2005; Mennink-Kersten  
et al. 2006; Mennink-Kersten et al.2008). Despite these shortcomings of both 
BDG tests, the EORTC/MSG Consensus Group included the GM and BDG 
detection methods in the diagnostic criteria for IFDs on the grounds of their 




1.2.2 Molecular testing 
 
 
1.2.2.1 Proteome analysis 
 
A novel promising approach to laboratory diagnosis of fungal infections is  
the employment of MALDI-TOF-MS technology facilitating the identification  
of potentially pathogenic microbes including fungi, based on the measurement  
of their characteristic protein expression patterns (Seng et al. 2010).  
An increasing number of papers demonstrate the potential of the method  
to accelerate the identification process and to broaden the spectrum of fungal 
species that can be identified (van Veen et al. 2010; De Carolis et al. 2011). 
However, this methodology can be influenced by cultivation conditions in some 
fungi. The utility of direct identification from the blood and other biological 
samples remains to be confirmed on large scale of fungal pathogens and types  
of specimens (Pfohler et al. 2009; Bille et al. 2011; Ferreira et al. 2011). 
 
 
1.2.2.2 Genome analysis 
 
Important limitations of available methods for the diagnosis of IFDs have led  
to the development of fungal nucleic acid detection techniques. Several hundred 
publications on the application of PCR for the detection of fungal DNA have 
appeared and provided a new diagnostic option displaying great potential. Major 
advantages of molecular methods include the high sensitivity and rapid 
availability of results, which permit timely onset of antifungal therapy.  
 
 
1.2.2.2.1 PCR formats  
 
PCR-based methods belong to the most frequently used approaches  
to molecular fungus analysis either permitting species-specific, genus-specific  
or broad-range (panfungal) fungus detection. Several molecular formats exist  
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for qualitative and/or quantitative detection and identification of fungi. Standard 
PCR (El-Mahallawy et al. 2006; Raad et al. 2002) and PCR-ELISA (Löffler et al. 
1998; Florent et al. 2006) belong to the first approaches established for clinical 
application, followed by nested PCR systems (Skladny et al. 1999; Holmes et al. 
1994) developed to improve the detection limit of the assay. At present, a number 
of different variations of RQ-PCR procedures are available, allowing 
quantification of fungal load and, depending on the setting of the assay, 
pathogen identification at the species level (Basková et al. 2007;  
Schabereiter-Gurtner et al. 2007). Moreover, special methods such as nucleic 
acid sequence-based amplification (NASBA) (Park et al. 2011), multiplex PCR 
followed by DNA microarray (Spiess et al. 2007), fragment size analysis  
of variable regions of the fungal genome (Landlinger et al. 2009a), DNA 
sequencing (Leaw et al. 2006), hybridization to specific capture probes bound  
to microbeads (Landlinger et al. 2009b) or pyrosequencing (Borman et al. 2010) 
have been developed to identify fungal pathogens in clinical samples.  
 
 
1.2.2.2.2 Target gene selection 
 
The growing spectrum of fungal pathogens involved in IFDs and the requirement 
of highly sensitive fungus detection necessitated the selection of appropriate 
target genes facilitating detection and/or identification of clinically relevant fungal 
pathogens at adequate sensitivity and specificity levels. A variety of single-  
or multi-copy genes were exploited to date for different molecular approaches. 
 
 
a) Single copy genes 
 
A number of PCR assays that target single-copy genes of yeasts, in particular 
Candida spp., have been tested. The genes including actin (Kan 1993), chitin 
synthase (Jordan 1994), heat shock protein 90 (Crampin and Matthews 1993) 
and gene for cytochrome P-450 lanosterol-14-alpha-demethylase (Buchman et 
26 
 
al. 1990) have been tested. Targeting the topoisomerase II gene permitted 
identification of four different Candida species and A. fumigatus (Kanbe et al. 
2003). In Aspergillus spp., copperzinc superoxide dismutase (Cu-ZnSOD) is  
a well-known potential marker of for IA. A recombinant Cu-ZnSOD  
of A. fumigatus has been produced by PCR amplification using homologous 
primers encoding the N-terminal sequence and the C-terminal region  
of the Cu-ZnSOD cDNA. The protein has been exploited as a diagnostic tool only 
to develop Western blot and ELISA assays for the detection of antibody 
responses in patients with IA. The option to target this protein in a PCR assay is 
worthy of consideration (Heldom et al, 2000).  
 There are limited data on PCR tests targeting single-copy genes  
for the detection of moulds other than Aspergillus spp. For the detection  
of Paracoccidioides brasiliensis, the gene encoding a 43 kDa glycoprotein (gp43) 
has been targeted (Bialek et al. 2000). Pneumocystis jiroveci was detected  
in BAL fluid targeting cell-division-cycle molecule 2 (Cdc2) (Arcenas et al. 2006). 
 
 
b) Multi-copy genes 
 
Ribosomal DNA gene. During recent years, the ribosomal DNA (rDNA) gene 
has been the most commonly targeted sequence offering the possibility  
to identify individual fungi (Landlinger et al. 2009a,b) or to detect a broad-range 
of fungal pathogens simultaneously (Löffler et al. 1998; Baskova et al. 2007; 
Schabereiter-Gurtner et al. 2007; Landlinger et al. 2010). The nuclear-encoded 
rDNA gene is a tandem array of at least 50-100 copies in the haploid genome  
of all fungi (Reiss et al. 1998). It exists as a multiple-copy gene family comprised 
of highly similar DNA sequences (typically 8-12 kb each) arranged  
in a head-to-toe manner. Each repeat unit is separated from the next  
by a non-transcribed region known as the intergenic spacer (IGS) region (Hillis 
and Dixon 1991). In nearly all basidiomycetes and several ascomycetes, the IGS 
is divided by the 5S rRNA gene into IGS1 and IGS2 (Fig. 1, Drouin and de Sá 
1995). In most filamentous fungi and most other eukaryotes, the IGS is not 
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interrupted, and the 5S rRNA gene is found elsewhere in the nuclear genome 
(Wolters and Erdmann 1989; Drouin and de Sá 1995). The small subunit (SSU) 
rRNA (18S) gene, the 5.8S gene and the large subunit (LSU) rRNA (28S) gene 
are transcribed as a single primary transcript which is subsequently cleaved 
during processing in the nucleus into three final molecules (Fig. 1). These three 
genes are separated by two internal transcribed spacers (ITS1 and ITS2) which 
contain signals for processing the primary transcript. Transcription of the 5S 
rRNA gene is distinct from the other three genes (Hillis and Dixon 1991). 
The coding regions of 18S, 5.8S and 28S nuclear rRNA genes evolved 
slowly, and are relatively conserved among fungi (White et al. 1990). The 18S 
region is about 1800 bp in size with both conserved and variable domain 
sequences. Sequence variations within this region have been used to assess  
the taxonomic relationship of the major groups of living organisms and  
to separate genera and species based on sequence polymorphisms (Einsele et 
al. 1997). However, the drawback in using this region for the identification  
of species is the relative sequence homology among species and the need  
to sequence a large number of bases for comparative analysis (Iwen et al. 2002).  
The 5.8S region, on the other hand, is only about 160 bp long and highly 
conserved among most fungal organisms. Owing to the small size and  
the conserved sequence, it is not appropriate for phylogenetic studies to classify 
fungal species. However, this conserved sequence has been useful as a binding 
site for universal primers for the amplification of flanking spacer regions within  
the eukaryotic genome (White et al. 1990).  
Finally, the 28S region, which is around 3400 bp in size in fungi, also 
contains both conserved and variable nucleotide sequences. In a study on RNAs 
from the large ribosomal subunit derived from eukaryotic cells, De Rijk (De Rijk et 
al 1996) reported that the length of sequences within the 28S region ranged  
from 2900 bp in yeast to over 5000 bp in Homo sapiens. Much of the 28S rRNA 
gene, however, is conserved among organism groups, thus limiting  
the usefulness of this region for species identification (Michot et al. 1984; Sandhu 
et al. 1995). 
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The ITS1 and ITS2 parts of the gene, which flank the 5.8S region, show 
extensive sequence diversity among major groups of eukaryotic organisms and 
even within species of the same organism group. Sequence sizes for each region 
vary from around 1000 bp in human cells to < 200 bp in some yeast (De Baere et 
al. 2002; Michot et al. 1984; Turenne et al. 1999). It was shown that these DNA 
spacers are also important for early transcription during rRNA processing (Iwen 
et al. 2002). 
The sequence composition of the rDNA complex allows the design  
of universal primers, based on the conserved regions, which will amplify a certain 
fragment of the rDNA gene cluster in a large number of fungal species. 
Moroever, it permits the design of species-specific primers and probes, based  
on the variable regions, which can be used to identify individual species. 
Furthermore, the presence of multiple copies of the rDNA gene cluster  
in the fungal genome provides a basis for highly sensitive detection. Panfungal 
RQ-PCR approaches were established to permit rapid and highly sensitive 
detection of previously rare fungal pathogens such as Mucorales, 
hyalohyphomycetes and yeast-like fungi in addition to a broad spectrum  
of Aspergillus and Candida species (Landlinger et al. 2010; Vollmer et al. 2008). 
 
 
Candida-secreted aspartic proteinase gene. The family of Candida-secreted 
aspartic proteinase genes (SAPs), which comprises at least nine related 
members in the C. albicans genome (De Bernardis et al 2001), are additional 
multi-copy genes that have been used as a target for the detection of C. albicans 
by PCR. Any number of unique primers can be designed to target specific 




Candida mitochondrial EO3 fragment. A 2- kb DNA fragment, EO3 present  
in multiple copies in the C. albicans genome was isolated for use in developing  
a detection method for serotypes A and B of C. albicans (Miyakawa et al. 1992). 
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Aspergillus mitochondrial b gene. The Aspergillus mitochondrial gene is  
an alternative multi-copy gene that may be targeted in PCR assays designed  
to detect Aspergillus spp. (Bretagne et al. 1995; Jones et al. 1998). 
 
 
Aspergillus alkaline proteinase gene. The family of alkaline proteinase 
enzymes in A. fumigatus is known to be responsible for most if not all  
of the extracellular elastinolytic activity of the organism (Kothary et al. 1984). 
Isolation and sequence analysis of fragments from the alkaline proteinase (ALP) 
gene in different Aspergillus species have allowed the design of complementary 
oligonucleotide primers that have provided useful diagnostic PCR tests  
(Urata et al. 1997). 
 
 
1.2.2.2.3 Technical aspects of fungal PCR 
 
A number of issues that arose in the studies performed could potentially affect 
the clinical applicability of PCR-based testing. These include technical aspects 
such as the selection of appropriate clinical specimens, including tissue samples, 
the required sample size, the efficacy and safety of DNA extraction procedures, 
the availability of carefully optimized and standardized amplification assays,  
the validation of the techniques in large clinical trials and, very importantly,  
the correct interpretation of results (Preuner and Lion 2009).  
 
 
a) Clinical samples 
 
A variety of clinical specimens have been employed for the detection of IFDs 
including whole blood, serum, plasma, BAL, cerebrospinal fluid, and fresh  
or paraffin-embedded tissue biopsies from affected sites. However,  
the occurrence of bleeding complications in immunocompromised individuals  
with severe thrombocytopenia is a serious impediment to sample collection 
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requiring invasive procedures. The most suitable blood fraction for molecular 
fungus detection has been a matter of debate.  
 
 
b) DNA extraction 
 
Investigation of plasma or serum specimens, in which free-circulating DNA is 
present, may require less complex and laborious extraction protocols. In contrast, 
the inclusion of additional steps was shown to be a prerequisite for effective 
isolation of cell-associated fungal DNA. The extraction protocols therefore often 
include a mechanic disruption step with glass beads (Fredricks et al. 2005),  
an enzymatic pre-treatment step using recombinant lyticase (Löffler et al. 1998) 
or the combination of both procedures (Baskova et al. 2007) to effectively release 
fungal DNA. Liquid clinical samples used for PCR analysis vary greatly between 
200 μl and 10 ml (Mengoli et al. 2009), where this fact may remain a particular 
problem of sufficient sample size in infants (Dornbusch et al. 2010). The fungal 
load in peripheral blood is mostly very low, ranging from less than 10 CFU/ml  
to a maximum of several hundred CFU/ml, a level rarely observed even  
in patients with proven fungal infection (Loeffler et al. 2002). These observations 
suggest that DNA extraction protocols that permit processing of larger initial 
samples volumes should be preferred. A plethora of different procedures  
for subsequent fungal DNA purification has been developed for manual or  
semi-automated applications showing comparable results. Some methods, 
particularly approaches including the use of spin-columns, appear to be more 
prone to carry-over contamination (White et al. 2006a).  
 
 
c) False positivity 
 
Contamination leading to false-positive results remains a major concern in PCR-
based assays. It may occur at diverse stages of sample processing, including  
the collection of patient material and several steps of specimen handling in  
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the laboratory. The main source of contamination caused by airborne fungal 
spores can be largely avoided by sample collection under aseptic conditions and 
the use of laminar air-flow units for sample handling in the laboratory. Moreover, 
utilization of closed extraction formats e.g. the MagnaPure system (Roche 
Diagnostics, Penzberg, Germany) may further contribute to reducing the risk  
of contamination (Basková et al. 2007). The observation of contamination  
with fungal spores or traces of fungal DNA in a variety of commercially available 
reagents and consumables implies the need for a number of safety measures. 
These include sterile filtration of all solutions for efficient removal of fungal 
spores, careful testing of all new reagents and materials for the presence  
of fungal DNA and inclusion of multiple negative controls.  
Beside the generation of false-positive results due to contamination, 
selection of an inappropriate detection system may be associated with other 
potential pitfalls. Screening methods for a broad range of fungal pathogens, 
which are preferred by the great majority of current molecular detection assays, 
exploit homologous regions within the fungal rDNA gene complex, as outlined 
above. Since these genes share significant homology with corresponding human 
genes, careful selection of PCR amplification and detection oligonucleotides is 
crucial to avoid co-amplification of human DNA and generation of false positive 
results (White et al. 2006). 
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Table 1.1. Laboratory methods in diagnostics of invasive fungal diseases 
 
Method Example Main use 
Convential   
Microscopy   
Wet preparation KOH, saline 
detection, mould 
identification 
Stained preparation Gram, Giemse, India ink 
detection, mould 
identification 
Flurescent dye staining Calcofluor 
detection (increased 
sensitivity) 
Culture   
Routine media Sabouraud isolation, cultivation 









 Mueller-Hinton, RPMI 1640 
antifungal susceptibility 
testing 
Histopathological   
Histological staining 
methenamine silver stain, 
haematoxylin-eosin, mucicarmin, 
Papanicolau 





Immnunofluorescence anti-Candida, anti-Aspergillus 
genus/species-specific 
detection 
Immunobiochemical   
Immunological   








Biochemical   
Fungal metabolites enolase, arabinitol/creatinine 
genus/species-specific 
detection 
Fungal cell components 1,3-beta-D-glucan detection 
Molecular   
Nucleic-acid based   
Amplification-based 




















Figure 1.1. Organization of the nuclear-encoded ribosomal DNA genes (rDNA)  
of fungi. (Drouin and De Sá 1995) The genes exist as a multiple-copy gene family 
comprised of highly similar DNA sequences, present in up to several hundred 
copies. Each repeat unit (typicaly 8-12 kb each) has coding regions for one major 
transcript (containing the primary rRNA for a single ribosome), interrupted by one 
or two intergenic spacer (IGS) regions depending on the presence of the 5S 
rRNA gene.  
SSU - small subunit, LSU - large subunit, ITS – internal transcribed spacer,  
IGS – intergenic spacer 
processing of the transcripts into individual rRNA molecules 
transcription of rDNA into rRNA 
SSU (18S) RNA 5.8S RNA LSU (28S) RNA 5S RNA 
ITS2 ITS1 IGS2 IGS1 






2.1  The Pan-AC assay: a single-reaction real-time PCR test  
for quantitative detection of a broad range of Aspergillus 
and Candida species 
 
 
2.1.1 AIM OF THE STUDY  
 
In the present study, we aimed at developing a rapid, sensitive and specific 
diagnostic test for the detection and accurate quantification of the most common 
pathogenic Candida and Aspergillus species. The design of the RQ-PCR assay 
should minimize the effect of point mutations on the detectability of the fungal 
species. No less importantly, the method should provide an economic approach 
to the screening and monitoring of invasive candidiasis and aspergillosis 
applicable to routine clinical diagnosis. This aspect was assessed  




2.1.2 MATERIALS AND METHODS 
 
2.1.2.1 Fungal strains, bacteria and virus isolates 
 
Fungal strains for PCR testing were obtained from the American Type Culture 
Collection (ATCC, Rockville, USA) and from the German Collection  
of Microorganisms (DSM, Braunschweig, Germany): Aspergillus fumigatus 
(ATCC 36607), Aspergillus niger (ATCC 10535), Candida albicans (ATCC 
14053), Candida dubliniensis (ATCC MYA-646), Candida glabrata (ATCC 2001), 
Candida krusei (ATCC 6258), Candida parapsilosis (ATCC 22019) and Candida 
tropicalis (ATCC 750), and Aspergillus flavus (DSM 818), Aspergillus nidulans 
(DSM 820), Aspergillus terreus (DSM 826), Aspergillus versicolor (DSM 1943), 
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Candida guilliermondii (DSM 70051), Candida kefyr (DSM 70073) and Candida 
lusitaniae (DSM 70102).  
Prior to DNA extraction, the fungal isolates were cultured on Sabouraud 
dextrose agar at 30 °C; Candida isolates were cultured for 48 h and Aspergillus 
isolates for 72 h. Suspensions of all fungi (Candida species, cell suspension; 
Aspergillus species, conidia suspension) were prepared using an aliquot  
of cultured fungus resuspended in sterile 0.9% NaCl solution. 
In addition, a panel of bacterial and viral microorganisms were selected  
for testing of cross-reactivity. The panel included Enterobacter aerogenes, 
Eschericha coli, Haemophillus influenzae, Listeria monocytogenes, 
Pseudomonas aeruginosa, Salmonella enteritidis, Staphylococcus aureus, 
Streptococcus pneumoniae, Proteus vulgaris, human adenoviruses, Epstein–Barr 
virus, cytomegalovirus, varicella-zoster virus, herpes simplex virus types 1 and 2, 
and parvovirus B19. 
 
 
2.1.2.2 Clinical materials 
 
The clinical specimens from patients with documented fungus infections were 
obtained upon informed consent. The specimens included biopsies of pulmonary 
infiltrations (n=2) and peripheral blood (n=3) from haemato-oncological patients, 
bronchotracheal secretions (n=11) from intensive care patients, and a cornea 
control specimen with a culture-documented infection by Fusarium solanii,  
which is outside the detection spectrum of the Pan-AC assay (kindly provided  
by St Anna Children’s Hospital, Vienna, Austria and the Institute of Hygiene and 
Medical Microbiology (IHMM) (Medical University of Vienna, Austria). Peripheral 
blood specimens from healthy volunteer donors were used to test for  
cross-reactivity with human DNA. 
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2.1.2.3 DNA extraction 
 
All steps were performed in a laminar flow hood using one-way sterile utensils. 
Reagents used for DNA extraction were filtered through 0.2 μm sterile filters 
(Corning®, Corning Inc., Germany). 
 
 
a) Fungal strains 
 
A colony of each fungus culture was homogenized in 500 μl lyticase lysis buffer 
(LLB) [50 mM Tris (pH 7.6), 1 mM EDTA (pH 8.0), 0.2% 2-mercaptoethanol,  
10 U/ml recombinant lyticase (Sigma, Steinheim, Germany)] and incubated  
at 37 °C for 2 h. After incubation, acid-washed glass beads 710–1180 μm  
in diameter (Sigma) were added and vortexed thoroughly for 2 min. A total  
of 400 μl supernatant were used for DNA extraction on a MagNA Pure compact 
instrument using the MagNA Pure compact nucleic acid isolation kit I (Roche 
Diagnostics, Penzberg, Germany) according to the manufacturer's instructions. 
The DNA was eluted in a total volume of 100 μl elution buffer (Roche 
Diagnostics). DNA concentrations were determined using the PicoGreen® dsDNA 
quantification kit (Molecular Probes Inc., Eugene, OR, USA) on the fluorescence 
spectrophotometer F-2500 (Hitachi, Japan). 
 
 
b) Peripheral blood specimens 
 
After hypotonic lysis of the erythrocytes from 3 ml blood using red cells lysis 
buffer [10 mM Tris (pH 7.6), 5 mM MgCl2, 10mM NaCl (all Sigma)], as described 
by Loffler et al. (1997), the leukocytes were pelleted and resuspended in 470 μl 




c) Respiratory secretions 
 
Samples were centrifuged at 5000 g for 10 min. The supernatant was removed 
and 430 μl LLB was added. The extraction was performed as described above. 
 
 
d) Solid specimens (e. g. lung biopsies and ocular specimens)  
 
Solid material was mechanically disrupted and homogenized in 1x PBS.  
The samples were centrifuged at 5000 g for 10 min, the supernatant was 




e) Bacteria and viruses 
 
For the isolation of DNA from cultured bacteria and virus stocks, a commercially 
available kit (QIAamp DNA mini kit; Qiagen GmbH, Hilden, Germany) was used 
as recommended by the manufacturer.  
 
 
2.1.2.4 Target sequence analysis and primer/probe design 
 
Conserved nucleotide sequences of the fungal ribosomal multi-copy genes (18S, 
5.8S and 28S) of clinically relevant Candida and Aspergillus species were 
selected and aligned using the BLAST search software, freely accessible  
at http://www.ncbi.nlm.nih.gov/BLAST/. Within the 28S large ribosomal subunit 
[between nucleotides 178 and 277 based on the sequence of the 28S rDNA gene 
of C. albicans (NCBI accession no. Z48339)], a highly conserved region was 
identified that spans less than 150 bp in length, thereby optimally fitting  
the requirements of RQ-PCR analysis using a hydrolysis TaqMan probe. 
Sequences for the forward primer, the reverse primer, and the universal probe 
(Table 2.1.2) were selected using Primer Express software (version 2.0; Applied 
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Biosystems) following the manufacturer’s guidelines (Table 2.1.3). The probe 
was labelled with FAM (6-carboxyfluorescein) as a reporter molecule  
at the 5´-end and TAMRA (6-carboxytetramethylrhodamine) as a quencher 
molecule at the 3´-end (Applied Biosystems). The optimal concentrations  
for the primers and the probe were assessed by serial analyses both  
from the functional and economic perspective, and were specified at 400 and  
200 nM, respectively. 
 
 
2.1.2.5 Real-time PCR 
 
PCR reactions were set up in a total volume of 25 μl containing 12.5 μl universal 
master mix [2x concentration, including ROX-reference dye and uracil  
N´-glycosylase (UNG)] [Applied Biosystems, (AB)], 1% formamide, a mixture  
of the forward and the reverse primer (400 nM each), 200 nM Pan-AC hydrolysis 
probe, and 5 μl genomic DNA (gDNA). The mixture was transferred to 96-well 
optical microtitre plates (AB). Amplification was performed on the ABI 7700 
sequence detection system (AB) using the following cycling parameters: 2 min  
at 50 °C (degradation of potentially present contaminating dUTP-containing 
amplicons by UNG), 10 min at 95 °C (inactivation of UNG and activation  
of AmpliTaq Gold DNA polymerase), followed by 50 cycles of 15 s at 95 °C and 
60 s at 60 °C for target amplification. For absolute quantification of the fungal 
DNA, standard curves were prepared using serial logarithmic dilutions covering  
a range of five logs (10 fg–100 pg) gDNA derived from C. albicans and  
A. fumigatus as positive control samples. 
 
 
2.1.2.6 Assessment of the detection limit 
 
To determine the detection limit of fungal pathogens in peripheral blood, 1 ml 
EDTA-anticoagulated whole blood from healthy volunteer donors was spiked  
with tenfold serial dilutions of A. fumigatus conidia and C. albicans cells  
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(105 to 100 cells). The number of fungal particles was determined microscopically 
using a counting chamber. DNA extraction was performed according  





A number of precautions were undertaken to control the occurrence  
of false-positive results. Multiple no-template and non-homologous template 
controls were processed together with the specimens tested, as described 
previously (Watzinger et al. 2004). To document the efficiency of DNA extraction 
and amplification, various positive controls were included, as already published 
(Lion 2001). In clinical samples containing human cells, a single-copy 
housekeeping gene (β2-microglobulin) was co-amplified in parallel  
with the fungal targets (Lion 2001). For largely cell-free human specimens, 
defined concentrations of a seal herpes virus were spiked into the sample prior  
to DNA extraction and analysed by RQ-PCR to control for the potential 
occurrence of inhibitory effects (Watzinger et al. 2004). 
 
 
2.1.3 RESULTS  
 
2.1.3.1 Specificity of the Pan-AC assay 
 
The ability of the Pan-AC system to detect all fungus species of interest  
(Table 2.1.1) was determined by testing DNA derived from cultures of reference 
strains, including C. albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, 
C. guilliermondii, C. kefyr, C. lipolytica, C. lusitaniae, C. dubliniensis,  
A. fumigatus, A. flavus, A. niger, A. terreus, A. versicolor and A. nidulans. Target 
sequences of all species were amplified successfully and showed nearly identical 
amplification efficiencies (data not shown). Based on the sequence alignment  
of additional, less common Aspergillus and Candida species, the Pan-AC  
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RQ-PCR assay can be expected to cover several other members of these two 
genera with similar sensitivity. 
The Pan-AC primers and probe (Table 2.1.2) were evaluated for possible 
cross-reactivity with bacterial or viral pathogens, both by sequence alignment 
using the BLAST software, and experimentally by testing the Pan-AC assay 
against bacterial and viral DNA from different organisms (see Methods). No 
crossreactivity between the Pan-AC primer/probe detection system and  
non-fungal pathogens was observed (data not shown). As indicated  
in Figure 2.1.1, DNA sequences from different human genes show significant 
homology with the fungal DNA sequence targeted by the Pan-AC assay. 
Analysing human DNA extracted from peripheral blood of healthy volunteer 
donors initially revealed some degree of crossreactivity. Different chemicals, 
including DMSO, glycerol and formamide, were tested in different concentrations 
(1–5%) to increase the stringency of the PCR reaction without simultaneously 
compromising the overall amplification efficiency. DMSO and glycerol completely 
inhibited the PCR reaction even at low concentrations (data not shown).  
By contrast, formamide concentrations of 1% abrogated the cross-reactivity  
with human DNA, while maintaining the high amplification efficiency of the PCR 
assay (Table 2.1.4). This concentration of formamide was, therefore, included 
both in the assessment of the detection limit and the testing of clinical specimens 
by the Pan-AC assay. 
 
 
2.1.3.2 Detection limit of the assay 
 
The detection limit of the Pan-AC assay was determined by testing serial 
dilutions of fungal gDNA derived from organisms representing yeasts  
(C. albicans) and moulds (A. fumigatus). The DNA concentration of the two 
fungal species was determined by fluorometric measurements, and serial 
logarithmic dilutions across a range of five logs (10 fg - 100 pg) were prepared. 
After PCR amplification, the cycle threshold (CT) values of individual dilutions 
steps were plotted against the template amount, leading to typical standard 
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curves (Figure 2.1.2). The Y-intercept, which corresponds to the theoretical limit 
of detection, was determined at CT 37.9 for C. albicans and CT 38.9  
for A. fumigatus. In view of the inter-assay variability of the technique in the range 
of ±1 CT, this difference can be regarded as minor. The amplification efficiencies 
of the Candida and Aspergillus species listed in Table 2.1.1 revealed only 
marginal differences (data not shown). The standard curves presented are, 
therefore, applicable in quantitative analysis of all fungal species covered  
by the Pan-AC assay. The lowest template amount permitting accurate and 
reproducible quantification of fungal DNA was in the order of 10 fg. 
In order to investigate the applicability of the Pan-AC assay to the analysis 
of clinical specimens, peripheral blood from healthy volunteer donors was spiked 
with tenfold serial dilutions of A. fumigatus conidia and C. albicans cells, covering 
a range between 105 to 100 organism/ml. The DNA was extracted and amplified  
as described in Methods. In patients with IFD, the fungal load in peripheral blood 
samples is generally low, often below 10 CFU/ml (Loeffler et al. 2000). Based  
on these observations, the sensitivity of the PCR assay is crucial for the detection 
and quantification of fungal pathogens. The detection limit of the Pan-AC assay 
in spiking experiments was less than 10 organisms per PCR reaction; however, 
for reproducible detection and quantitative analysis a higher volume of peripheral 




2.1.3.3 Analysis of clinical specimens 
 
The Pan-AC assay was employed to investigate specimens from 17  
haemato-oncological or intensive care patients with fungal infections diagnosed 
by other methodological approaches, including primarily culture techniques and 
DNA sequencing. According to the EORTC criteria, 4 patients were classified  
as having a possible IFD and 12 patients a probable IFD infection (Table 2.1.5, 
samples 1–16). Only for the patient from whom the cornea specimen was 
derived, was no EORTC classification available (Table 2.1.5, sample 17). 
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The Pan-AC assay revealed positive results in the clinical specimens 
studied, including lung biopsies of patients with pulmonary aspergillosis  
or candidiasis, peripheral blood specimens from patients with different types  
of candidaemia, and respiratory secretions positive for different Aspergillus 
species (Table 2.1.5). In one of the latter specimens, co-infection with  
C. lusitaniae was detected (Table 2.1.5, sample 13). The only clinical sample that 
tested negative by the Pan-AC assay was a cornea specimen, in which culture 
analysis revealed the presence of F. solanii. This specimen only served  
as a control because this fungus is not within the detection spectrum of the PCR 
assay presented (Table 2.1.5). Quantitative analysis of the fungal load  
in specimens positive by RQ-PCR was performed by using the appropriate 
standard curves, and the amount of fungal DNA determined was translated  
to the number of organisms on the basis of the estimated mean genome masses 





In the present report, a RQ-PCR assay is described permitting the detection and 
quantification of a broad range of clinically relevant Aspergillus and Candida 
species (Table 2.1.1) in a single reaction. A single primer pair and a universal 
probe were designed within a highly conserved region of the 28S large ribosomal 
subunit (Figure 2.1.1). The selected primer and probe sequences display  
a degenerated code (Table 2.1.2), which was a prerequisite for sensitive 
detection of fungal species differing from others at single nucleotide positions.  
A major problem of fungal PCR assays is the high risk of contamination 
(Loeffler et al. 1999), which is attributable to the ubiquitous presence of airborne 
fungal spores, and traces of fungal DNA in a variety of reagents and other 
consumables. To avoid false-positive results, it is imperative therefore to control 
all materials used, both self-made and commercially available, for fungal 
contaminants, and to include multiple negative controls in each assay.  
The fungus detection assays must be performed under adequate experimental 
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conditions, which include the preparation of reagents and processing of clinical 
samples under a laminar flow biohazard hood. With appropriate precautions and 
controls, the RQ-PCR assay presented can serve as a reliable diagnostic tool  
for the detection and quantitative monitoring of pathogenic fungi in clinical 
specimens for the presence of IFD. 
In patients testing positive, antifungal agents, such as voriconazole  
or caspofungins, could be used as first-line treatment, because these substances 
can be expected to cover the entire range of fungi detected by this assay.  
The use of agents with a narrower spectrum of antifungal activity,  
such as fluconazole or amphotericin B, would require the identification  
of the fungal species present, which can be performed by a number of molecular 
techniques, including, for example, the analysis of the variable ITS2 region  
or species-specific hybridization (Chen et al. 2000; Elie et al. 1998; Sandhu et al. 
1995; Turenne et al. 1999). 
In comparison to most earlier RQ-PCR approaches to the detection  
of invasive aspergillosis or candidiasis (Bu et al. 2005; Buchheidt et al., 2004; 
Kami et al., 2001; Kasai et al., 2006; Klingspor & Jalal, 2006; Spiess et al., 2003), 
the Pan-AC assay covers a considerably larger spectrum of pathogenic 
Aspergillus and Candida species in a single reaction, using a universal detection 
probe and a single primer pair. Our data indicate that the Pan-AC assay can be 





Table 2.1.1. GenBank accession numbers of fungal species used  
for 28S rDNA alignment and selection of sequences targeted by the Pan-AC 
assay. 
Name NCBI Acc. No. 
Candida albicans Z48339, X83717, L28817 
Candida dubliniensis U57685, AB031020 
Candida glabrata U44808, Z48341 
Candida guilliermondii AF374616, U45709 
Candida kefyr AF335978, Y15476 
Candida krusei U76347, Z48567 
Candida lipolytica AF335977 
Candida lusitaniae U44817 
Candida parapsilosis AF374609, Z48343 
Candida tropicalis AF267497, Z48346 
Aspergillus flavus AF027863, U28899 
Aspergillus fumigatus AF109335, U28460, Z48340 
Aspergillus nidulans AF109337, U29856 
Aspergillus niger U28815, AF109344 
Aspergillus terreus U28841, AF109340 

















Fw primer  TGGGTGGTAAATTYCATCTAAAGCTA C. albicans Z48339 185-210
*
 400 
Rev primer  CAAGTKCTTTTCATCTTTCSWTCAC C. albicans Z48339 245-270
*
 400 









Table 2.1.3. TaqMan® Primer/Probe design using the Primer Express ™ 
software: guidelines and recommendations 
 Probe Primers 
GC content 20-80% 
the strand with more Cs 
than Gs should be selected 
the five nucleotides at the 
3’ end should have no 




avoid stretches of identical nucleotides, particularly Gs; 
clusters of four or more Gs should be avoided 
Melting 
temperature (Tm) 
in a single-probe assay 68-
70°C for TaqMan® Probe  
58-60°C 
 avoid design of probes with 
a G residue at the 5’ end 
design the primers as 
close as possible to the 
probe without overlaps  
 
 
Most consistent results are obtained for amplicon size ranges from 50-150 bp  
The primers should be chosen according to the probe. 




Table 2.1.4. Influence of formamide concentration on the threshold cycle (CT) 
and the fluorescence intensity of the reporter (∆Rn). The effect was tested  
for different fungus DNA template concentrations of both Candida and 
Aspergillus representatives ranging from 1 pg to 10 fg. The RQ-PCR results 
shown represent the effect of formamide observed in the lowest fungal 
template concentration tested (10 fg DNA of C.albicans). Although the overall 
fluorescence intensity decreased with rising concentrations of formamide,  
the concentration at which any cross-reactivity with human DNA was 
abrogated (1%) generally revealed only slightly increased CT values. 
 
Formamide conc. % CT 
value 
Rn 
0 33.60 2.41 
0.5 34.17 1.72 
1 34.12 1.55 
1.5 35.46 1.10 
2 36.61 0.95 






















1 blood probable C.glabrata N.D. positive  34.8 8 
2 blood possible N.D. C.albicans positive  28.1 600 
3 blood possible N.D. C.krusei positive  37.0 2 
4 lung biopsy possible N.D. A.fumigatus positive  35.7 4 
5 lung biopsy possible N.D. C.lipolytica positive  30.7 130 
6 respiratory tract probable A.fumigatus, A.niger N.D. positive  27.2 1429 
7 respiratory tract probable A.fumigatus N.D. positive  32.4 40 
8 respiratory tract probable A.fumigatus N.D. positive  31.6 69 
9 respiratory tract probable A.fumigatus N.D. positive  26.1 2885 
10 respiratory tract probable A.fumigatus N.D. positive  29.8 246 
11 respiratory tract probable A.nidulans N.D. positive  32.4 40 
12 respiratory tract probable A.fumigatus, A.flavus N.D. positive  29.9 230 
13 respiratory tract probable A.fumigatus, C.lusitaniae N.D. positive  35.7 4 
14 respiratory tract probable Aspergillus spp. N.D. positive  33.5 19 
15 respiratory tract probable A.fumigatus N.D. positive  32.5 40 
16 respiratory tract probable A.fumigatus N.D. positive  31.5 78 
17 cornea  F.solanii N.D. negative   
 
ND Not determined 
 
* The diagnosis of IFD was performed according to the EORTC criteria 
(http://www.doctorfungus.org/lecture/eortc_msg_rev06.htm) 
+ The numbers indicate the determined amount of fungal DNA at the beginning  
of the PCR-reactions. To calculate the fungal load in the clinical specimen 
investigated, the quantity of fungal DNA in femtograms assessed by RQ-PCR 
analysis can be translated to the number of fungal organisms on the basis  
of the estimated genome mass (Aspergillus 32 fg, Candida 37 fg) and  





NCBI Acc. No.    Species              Position releated to C.albicans Z48339 
                                      178                                                                                              277 
Z48339           C.albicans           CTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGAACTTTGAAAAGAG 
U57685           C.dubliniensis       CTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGAACTTTGAAAAGAG 
U44808           C.glabrata           CTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATACAGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGAACTTTGAAAAGAG 
AF374616         C.guilliermondii*    CTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGAACTTTGAAAAGAG 
AF335978         C.kefyr*             CTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGAACTTTGAAAAGAG 
U76347           C.krusei*            CTCCAAGCGGGTGGTAAATTCCATCTAAGGCTAAATACTGGCGAGAGACCGATAGCGAACAAGTACTGTGAAGGAAAGATGAAAAGCACTTTGAAAAGAG 
AF335977         C.lipolytica*        CTCAAAGTGGGTGGTAAACTCCATCTAAAGCTAAATACTGGTGAGAGACCGATAGCGAACAAGTACTGTGAAGGAAAGGTGAAAAGAACTTTGAAAAGAG 
U44817           C.lusitaniae*        CTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGCACTTTGAAAAGAG 
AF374609         C.parapsilosis       CTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGAACTTTGAAAAGAG 
AF267497         C.tropicalis         CTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGAACTTTGAAAAGAG 
 
U28889           A.flavus             CTCTAAATGGGTGGTAAATTTCATCTAAAGCTAAATACTGGCCGGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
U28460           A.fumigatus          CTCTAAATGGGTGGTAAATTTCATCTAAAGCTAAATACTGGCCGGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
U29859           A.nidulans*          CTCTAAATGGGTGGTAAATTTCATCTAAAGCTAAATACCGGCCGGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
U28817           A.niger              CTCTAAATGGGTGGTAAATTTCATCTAAAGCTAAATACTGGCCGGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
U28845           A.terreus            CTCTAAATGGGTGGTAAATTTCATCTAAAGCTAAATACTGGCCGGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
AF454195         A.versicolor         CTCTAAATGGGTGGTAAATTTCATCTAAAGCTAAATACCGGCCGGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
 
 
M11167           Human 28S rib. gene  CCCAAAGCGGGTGGTAAACTCCATCTAAGGCTAAATACCGGCACGAGACCGATAGTCAACAAGTACCGTAAGGGAAAGTTGAAAAGAACTTTGAAGAGAG 
U13369           Human ribosomal DNA  CCCAAAGCGGGTGGTAAACTCCATCTAAGGCTAAATACCGGCACGAGACCGATAGTCAACAAGTACCGTAAGGGAAAGTTGAAAAGAACTTTGAAGAGAG 
 
                                             185                    210      217                   241   245                    270 
Oligonucleotide sequences                    TGGGTGGTAAATTYCATCTAARGCTA      CCGSYCTCTGGCTATCGCKTGTTCA   CACTWSCTTTCTACTTTTCKTGAAAC 
for the Pan-AC RQ-PCR assay                  5’                       3’     3’                      5   3’                       5’ 








Figure 2.1.1. Multiple sequence alignment (Corpet F 1988) of a highly conserved region within the 28S rDNA gene of ten 
Candida species, six Aspergillus species and the corresponding region from the human genome. The primer pair and the 
probe (grey boxes) for the Pan-AC RQ-PCR assay were placed within this region. The indicated nucleotide positions refer 
to the sequece of C.albicans (NCBI accession no. Z48339). The asterisks indicate species that are listed under other 
names in the NCBI database: C. guilliermondii = NCBI Pichia guilliermondii, C. kefyr = NCBI Kluyveromyces marxianus, 
C. krusei = NCBI Issatschenkia orientalis, C. lipolytica = NCBI Yarrowia lipolytica, C. lusitaniae = NCBI Clavispora 





Figure 2.1.2. Amplification plots (a, b) and standard curves (c, d) based on serial 
dilutions of fungal gDNA ranging from 10 fg to 100 pg, derived  
from representatives of yeasts (C. albicans) (a, c) and moulds (A. fumigatus)  








































































2.2  Diagnosis of invasive fungal diseases by a real-time 
 panfungal PCR assay in immunocompromised patients 
 
 
2.2.1 AIM OF THE STUDY 
 
IFD is a life-threatening event in immunocompromised patients, and there is 
urgent need for reliable screening methods facilitating rapid and reliable broad 
detection of pathogenic fungi. To address this task, we aimed at establishing  
a RQ-PCR assay for detection of a wide spectrum of fungal pathogens including 
fungal species of both common and emerging fungal genera. The potential 
clinical utility of the assay was assessed in a combined prospective and 
retrospective study in severely immunocompromised pediatric patients displaying 
a high risk of IFD. 
 
 
2.2.2 MATERIALS AND METHODS 
 
2.2.2.1 Fungal strains, bacteria, and viral isolates 
 
Fungal strains for PCR testing (Table 2.2.1) were obtained from different 
institutions including the ATCC, (Rockville, USA), the DSM, (Braunschweig, 
Germany), and the IHMM, (Medical University of Vienna, Austria). 
 
 
2.2.2.2 Clinical materials 
 
Clinical specimens from consecutive patients were obtained after informed 
consent, and were prospectively collected as specified below. In total,  
618 peripheral blood specimens from 125 pediatric hemato-oncological patients 
undergoing intensive chemotherapy (n=65) or allogeneic stem cell 
transplantation (n=60) were analyzed during 150 episodes of febrile neutropenia. 
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Whenever possible, specimens were collected at first onset of fever,  
within 48 hours thereafter, and at subsequent time points in the course  
of the febrile episode, upon availability. On average, four peripheral blood 
samples were investigated during each episode (range 1-15). In selected 
instances, depending on availability, additional types of specimens derived  
from primarily sterile sites of suspected infection were collected and subjected  
to molecular analysis. These included cerebrospinal fluid (n=11) and lung 
biopsies (n=2) in patients with suspected CNS or pulmonary involvement, 
respectively, in order to correlate the data with PCR findings in peripheral blood 
samples. The specimens used as training set for initial data assessment were 
provided by the Erasmus MC-Sophia Children's Hospital, Rotterdam,  
the Netherlands, and the specimens used as validation set by the St. Anna 
Children’s Hospital of Vienna, Austria. Plasma or serum was usually collected 
from 3 ml samples of peripheral blood and all samples were stored at -80°C  
until further processing. Peripheral blood specimens from healthy volunteer 
donors were used to test for cross-reactivity with human DNA (see below). 
 
 
2.2.2.3 DNA extraction 
 
The isolation and purification of DNA from fungal strains, as well as of fungal, 
human, bacterial and viral DNA from different clinical materials was performed 
essentially as described earlier (Baskova et al. 2007).  
 
 
2.2.2.4 Real-time PCR  
 
The panfungal PCR detection assay included two separate reactions, I and II, 
each covering different subsets of fungal pathogens, as outlined in Table 2.2.1. 
Both PCR reactions targeted a highly conserved region of the 28S rRNA 
multicopy gene (Figure 2.2.1). The PCR reactions were set up in a total volume 
of 25 µl containing Gene Expression Mastermix 2x with UNG (AB, Foster City, 
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USA), primers and probes as listed in Table 2.2.2, and molecular biology grade 
water (Eppendorf, Hamburg, Germany). Locked nucleic acid (LNA) nucleotides 
were included in the primer and probe sequences to obtain high specificity 
despite short length (Tolstrup et al. 2003). The amplification was performed  
on a TaqMan 7900 instrument using the following standard protocol: 2 min  
at 50°C (UNG-mediated degradation of potentially present contaminating 
amplicons containing dUTP), 10 min at 95°C, followed by 50 cycles of 15 s  
at 95°C and 1 min at 60°C (Watzinger et al. 2004). 
 
 
2.2.2.5 Assessment of cross-reactivity with bacterial, viral and human DNA 
 
Potential cross-reactivity of the panfungal detection assay with non-fungal 
microorganisms was analyzed by testing a total of 20 different bacterial and viral 
pathogens. Multiple isolates of DNA derived from different human peripheral 






A number of positive and negative controls were included in the panfungal  
real-time assay as described earlier (Watzinger et al. 2004). In view of the lack  
of “fungus-grade” reagents guaranteed to be free of contamination by fungal 
particles or DNA, highly stringent measures to control and exclude contamination 




2.2.2.7 Specificity of the real-time PCR assays 
 
Differences in the detection efficiency of individual pathogens determined  
by testing defined concentrations of fungal species were in the range  
53 
of +/-1 CT value. The only exceptions were the fungal species Geotrichum 
candidum, Malassezia furfur, Mucor hiemalis, Candida lipolytica, and 
Acremonium strictum which revealed higher CT values (in the range of +3), 




2.2.2.8 Sensitivity of the real-time PCR assays 
 
To determine the detection limit of the real-time PCR assays, serial logarithmic 
dilutions across a six-log range (1 fg to 100 pg) of genomic DNA derived  
from A. fumigatus and C. albicans, as representatives for moulds and yeasts, 
respectively, were analyzed. Standard curves were generated on the basis  
of the amplification profile (Figure 2.2.2). 
 
 
2.2.2.9 Definition of PCR positivity and DNAemia 
 
All clinical specimens were analyzed in duplicates. A PCR result was regarded  
as positive when both CT values were either ≤ 36.5 in reaction I or ≤ 37.5  
in reaction II, reflecting the respective y-intercept values. In the event of single 
positive values of the duplicate measurement, the CT had to be ≤ 34.5 in reaction 
I and ≤ 35.5 in reaction II to be regarded as PCR-positive. For the diagnosis  
of fungal DNAemia, a minimum of two PCR-positive peripheral blood specimens 
derived at subsequent time points during close follow-up investigation were 
required. In the rare instances in which only one specimen from a febrile 
neutropenic episode was available, a single PCR-positive result was regarded  
as indicative of DNAemia. 
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2.2.2.10 Statistical analysis 
 
Results of panfungal PCR analysis in relation to the presence or absence  
of possible, probable, or proven IFD by the EORTC criteria were used  
for the calculation of sensitivity and specificity, and the corresponding negative 
(NPV) and positive predictive values (PPV) of the assay. Individual values and 
the corresponding 95% confidence intervals (CI) were calculated using  





2.2.3.1 Design and principle of the panfungal PCR assay 
 
The universal primers and probes for the two-reaction panfungal PCR assay 
were judiciously selected on the basis of their homology to highly conserved 
sequences within the 28S gene based on the sequence alignment of more than 
80 fungal species (Tables 2.2.1 and 2.2.2). The primers display a degenerated 
code required for efficient amplification of fungal species that differ from others  
at single nucleotide positions. In order to obtain optimal binding affinity, LNA 
modifications of individual nucleotides were included in the hybridization probes 
and the reverse primers (Table 2.2.2). Owing to the exploitation of a multi-copy 
target gene, the detection limit of the panfungal PCR assay is in the range of 1 fg 
fungal DNA per reaction, which corresponds to a fraction of a single fungal 
genome equivalent (Figure 2.2.2). 
 
 
2.2.3.2 Detection spectrum and specificity of the panfungal PCR assay 
 
To document the detection spectrum of the two-reaction panfungal PCR assay, 
multiple strains/isolates of 61 different fungal species (Table 2.2.1), were 
analyzed experimentally in repeated tests. However, based on extensive 
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sequence alignments, the panfungal real-time PCR assay presented can be 
expected to cover more than 80 different fungal species (Table 2.2.1). Reaction I 
was designed to permit detection and quantitative assessment of a variety  
of moulds (n≥ 29), whereas reaction II targets a broad range of yeasts and 
Zygomycetes (n≥ 58). The assay therefore permits the detection of co-infections 
by different fungal genera, which may not be uncommon in immunocompromised 
individuals. 
Cross-reactivity between reactions I and II was observed at a high 
concentration of fungal template DNA (≥ 100fg/reaction). However,  
the amplification efficiencies for moulds and yeasts/Zygomycetes  
by the appropriate detection systems were about 3 logs higher, thereby 
permitting clear identification of the dominant class of fungal pathogen present. 
At the concentrations of fungal pathogens observed in most clinical specimens  
of immunocompromised individuals, the cross-reactivity was not relevant.  
The lack of cross-reactivity of the panfungal PCR assay with non-fungal 
pathogens or human genomic DNA was assessed by extensive testing of various 
bacterial and viral DNA isolates, and peripheral blood specimens of healthy 
volunteer donors, as specified in the Materials and Methods section. 
 
 
2.2.3.3 Analysis of clinical specimens by the panfungal PCR assay  
in relation to the EORTC criteria for IFD 
 
The analyses of clinical specimens were performed in a double-blind fashion  
to prevent any bias or influence on treatment decisions. First, a training set  
of 165 peripheral blood specimens derived from 43 pediatric patients with high 
risk of IFD was analyzed by the panfungal PCR assay in a retrospective study  
in order to generate preliminary data on the potential clinical utility of the test 
system. The patients were generally in febrile neutropenia at the time of sample 
collection. In total, 71 specimens (43%) tested PCR-positive, 34 in reaction I,  
15 in reaction II, and 22 in both reactions with CT values clearly beyond the level 
of potential cross-reactivity. The results of molecular testing were evaluated  
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in relation to the criteria proposed by the EORTC (De Pauw et al. 2008), and 
indicated that all patients with proven or probable IFD, and all but one case  
with possible IFD tested repeatedly PCR-positive, as specified in Table 2.2.3.  
In three instances, both PCR reactions revealed positive results indicative  
of mixed infections (Table 2.2.3). 
Five patients received empirical antifungal therapy on the basis of clinical 
suspicion of fungal infection, which did not meet the EORTC definition of possible 
IFD (generally by absence of an appropriate clinical criterion), and three of these 
patients were also positive by the panfungal PCR assay (Table 2.2.3). However, 
consecutive PCR-positive results were also obtained in 6 of 27 instances with no 
clinical indication of IFD in patients who were on antifungal prophylaxis only  
or did not receive any kind of antimycotic treatment (Table 2.2.3). Hence, 
analysis of the training data set indicated a good correlation between repeated 
positivity of the panfungal PCR assay and the presence of proven, probable, and 
possible IFD by the EORTC criteria, by revealing a sensitivity of the panfungal 
screening assay of 91% (95%CI: 62-98%), and a NPV of 95% (95%CI:78-99%). 
Although it might be more appropriate to calculate the NPV of the panfungal PCR 
assay on the basis of proven and probable IFD only, we have also included 
patients classified as having a possible IFD in the calculation in order to obtain  
a value applicable to any level of IFD according to the EORTC criteria. 
A problem in the specificity of panfungal PCR-positive results became 
particularly apparent in the presence of single positive tests, and in follow-up 
samples collected at extended time intervals (>3 days) during febrile neutropenia. 
Based on the presence of positive PCR tests, according to the definition 
indicated in Materials and Methods, the specificity of the assay was 78% 
(95%CI:59-89%), and the PPV 63% (95%CI:39-82%). 
On the basis of insights gained from analysis of the training set, a larger 
cohort of immunocompromised pediatric patients was investigated, with a focus 
on febrile neutropenic episodes and the requirement of consecutive samples 
collected at short time intervals (1-2 days). A total of 453 consecutive peripheral 
blood samples derived from 107 febrile neutropenic episodes in 82 pediatric 
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patients with hemato-oncological malignancies (n=22) or hematopoietic stem cell 
transplant recipients (n=60) were analyzed. Similar to the first cohort tested,  
212 specimens (47%) tested PCR-positive, 122 in reaction I (58%), and 45  
in reaction II (21%). Forty five samples (21%) were positive in both reactions, 
with differences in CT values clearly beyond the level of potential cross-reactivity, 
hence indicating a mixed infection. Overall, 51 of 107 febrile neutropenic 
episodes investigated revealed repeatedly positive test results by the panfungal 
real-time PCR assay (Table 2.2.4). There was no statistically significant 
difference between allogeneic stem cell transplant recipients and non-transplant 
patients with regard to the occurrence of panfungal PCR-positivity in peripheral 
blood during the neutropenic febrile episodes (50% vs 39%; two-sided  
p-value = 0.29). PCR-positivity was observed in all cases of IFD according  
to EORTC criteria (n=16), revealing a sensitivity of 100% (95% CI: 81-100%) and 
an NPV of 100% (95% CI: 90%-100%).  
All patients with proven, probable, and possible IFD (n=16) tested 
repeatedly PCR-positive, as specified in Table 2.2.4. In five instances, both PCR 
reactions revealed positive results indicative of mixed infections with different 
fungal genera (Table 2.2.4). In all 16 patients with IFD, positive PCR results were 
already detected in the specimens collected at first onset of fever within a febrile 
neutropenic episode. 
In 48 instances, patients with febrile neutropenia received empirical 
antifungal treatment despite the lack of findings supporting the presence of IFD 
according to the EORTC criteria. Only 25 of these patients revealed evidence  
of IFD by panfungal PCR analysis (Table 2.2.4). In patients with no clinical 
indication of IFD, including individuals receiving antifungal prophylaxis only and 
individuals without any antimycotic treatment, repeatedly positive test results  
by the panfungal PCR assay were obtained in 10 of 43 (23%) febrile neutropenic 
episodes (Table 2.2.4). The observations made in the validation patient cohort 
therefore reflected a specificity of the assay at the level of 77% (95% CI:62-87%) 
and a PPV of 62% (95% CI:42%-76%). 
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Evaluation of the molecular assay in both patient cohorts combined 
revealed a sensitivity of 96% (95%CI:82-99%), and a specificity of 77% 
(95%CI:66-85%), corresponding to a NPV of 98% (95%CI:90-100%), and a PPV 





Over the last years, a small number of prospective studies have assessed  
the clinical utility of different PCR assays in hematopoietic stem cell 
transplantation recipients and/or patients with hematological malignancies 
(Jordanides et al 2005; Klingspor and Jalal 2006; Hebart et al. 2000; Boudewijns 
et al. 2006; Buchheidt et al. 2001). The reported sensitivity and the NPV were 
moderate to high. The specificity was generally lower, but could be significantly 
improved by establishing the requirement of two consecutive positive PCR 
results as a diagnostic criterion (Cuenca-Estrella et al. 2009; Mengoli et al. 2009). 
However, the diagnostic reliability of PCR assays in peripheral blood and serum 
specimens has been described to be rather limited (White et al. 2006a;b). 
The panfungal real-time PCR assay presented was specifically adapted  
to highly sensitive detection of fungal pathogens in peripheral blood or serum.  
In the current combined prospective and retrospective study, more than  
600 clinical specimens from 150 febrile neutropenic episodes in pediatric patients 
with high risk of invasive fungal disease were investigated by the panfungal  
real-time PCR assay described. Evaluation of the molecular screening data, 
which had been generated in a double-blind fashion, revealed an excellent 
correlation with the EORTC definitions of proven, probable, and possible invasive 
fungal disease. The sensitivity and the NPV in the validation cohort of patients 
were in the range of 100% indicating that molecular screening might be 
instrumental in preventing unnecessary treatment. The possible benefit of this 
notion is underlined by the observation that nearly half of the febrile neutropenic 
episodes studied were treated empirically by antifungal agents, despite the lack 
of evidence for IFD according to the EORTC criteria. The absence of fungemia 
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determined by the panfungal PCR assay in about 50% of these episodes 
suggests that a high proportion of patients were probably over-treated. 
The limited specificity and PPV of the panfungal PCR assay reflect the fact 
that even in severely immunocompromised patient populations, repeated  
or persistent detection of fungemia by sensitive, broad-spectrum PCR methods 
may not generally indicate an imminent risk of severe fungal disease. This 
observation might be interpreted as frequent occurrence of false positivity, most 
likely attributable to contamination. However, owing to the processing of test 
materials in a sterile environment, the use of internally tested reagents and  
the number of controls included in each assay, it may be an explanation  
for some, but very likely not all seemingly false-positive findings.  
Of the PCR-positive patients who received either no antifungal treatment at all  
or prophylaxis only (n=16), fungal disease was diagnosed during the subsequent 
clinically documented febrile episode early thereafter in two patients, raising  
the possibility that subclinical fungemia was present at the time of the febrile 
episode investigated. In two additional patients, fungus-positive cultures  
from urine and throat were obtained at the time of PCR positivity, indicating  
the presence of fungal infection or colonization. However, based on the current 
EORTC criteria, these patients could not be classified as having IFD at any level 
of probability. In five patients, treatment with semi-synthetic penicillins was 
documented during the febrile episodes investigated. These substances were 
reported to yield false-positive results in serological fungus detection tests, and it 
cannot be excluded that the occurrence of cross-reactivity with molecular 
detection assays might have accounted for false positivity of the panfungal PCR 
assay. In seven patients, no findings possibly explaining the PCR-positive results 
could be identified.  
The limited correlation between positive panfungal PCR results and 
imminent fungal disease may also reflect the relatively common occurrence  
of fungemia caused by environmental fungi, such as Alternaria or Cladosporium 
species, which might display low pathogenicity even in immunosuppressed 
individuals (Aimanianda et al. 2009; Pastor and Guarro 2008). To assess this 
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notion, clinical implementation of methods facilitating reliable identification  
of these species at an adequate level of sensitivity would be required. A number 
of methods for rapid typing of fungal pathogens have been published (Chen et al. 
2000; De Baere et al. 2002; Landlinger et al. 2009a; Turenne et al. 1999;  
Das et al. 2006; Diaz and Fell 2004; Boyanton et al. 2008; Putignani et al. 2008; 
Campa et al. 2008; Spiess et al. 2007; Zeng et al. 2007), and the development  
of novel and expectedly more potent methods is currently underway, including 
also approaches based on the exploitation of nano-technological devices 
(Landlinger et al. 2009b). Rapid and sensitive techniques for the identification  
of putatively non- or low-pathogenic environmental fungal species that may 
cause clinically silent fungemia could improve the interpretation of results 
obtained by broad-spectrum PCR screening methods. This might contribute  
to increased specificity of molecular monitoring with regard to more reliable 
assessment of the expected clinical relevance of fungemia. Hence, routine 
clinical implementation of methods for rapid identification of fungal species could 
provide a basis for better assessment of the need for treatment and for selection 
of the most appropriate antimycotic agent, if therapy appears to be required. 
The lack of a gold standard for the assessment of IFD presents a problem 
in the interpretation of new diagnostic approaches. The criteria of proven, 
probable, and possible IFD proposed by the EORTC are widely accepted, but  
the diagnostic tests permitting the assessment of proven or even probable 
infection, such as histological examination of targeted biopsies, image-guided 
analyses (e.g. computer tomography), blood cultures, and serological tests are 
not available in many high-risk patients including also a large proportion  
of patients in the present study. The reliability of serological testing  
by galactomannan in pediatric patients is, however, questionable. It has been 
reported that galactomannan tests frequently yield false-positive results  
in the pediatric population. This observation was mainly attributable to dietary 
factors [e.g. various brands of milk formulas (Gangneux et al. 2002; Steinbach 
2005) or soybean protein (Murashige et al. 2005)] and, in the general population, 
to the use of semi-synthetic penicillins (Adam et al. 2004; Zandijk et al. 2008). 
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Routine employment of a broader set of diagnostic methods including  
image-guided analysis, blood culture, and serological testing in carefully 
designed clinical studies would be required to assess and finally exploit the full 
diagnostic potential of the panfungal PCR screening assay presented.  
The design of appropriate large-scale clinical studies is currently underway. 
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Table 2.2.1. Fungal species/isolates detected by the panfungal RQ-PCR assay 
Reaction I Reaction II 
Experimetally tested Experimetally tested 
Acremonium strictum Absidia corymbifera 
Alternaria alternata Blastoschizomyces capitatus 
Aspergillus candidus Candida albicans 
Aspergillus clavatus Candida allociferrii 
Aspergillus flavus Candida colliculosa 
Aspergillus fumigatus Candida cylindracea 
Aspergillus glaucus Candida dubliniensis 
Aspergillus nidulans Candida famata 
Aspergillus niger Candida glabrata 
Aspergillus terreus Candida guilliermondii 
Aspergillus versicolor Candida inconspicua 
Fusarium oxysporum Candida kefyr 
Fusarium proliferatum Candida krusei 
Fusarium solani Candida lambica 
Fusarium verticillioides  Candida lipolytica 
Penicillium chrysogenum Candida lusitaniae 
Penicillium citrinum Candida membranaefaciens 
Penicillium marneffei Candida norvegensis 
Penicillium purpurogenum Candida parapsilosis 
Penicillium simplicissmum Candida pelliculosa 
Scedosporium apiospermum Candida rugosa 
 Candida sake 
Based on sequence alignments Candida tropicalis 
Aspergillus ochraceus Candida utilis 
Aspergillus penicillioides Candida zeylanoides 
Aspergillus ustus Cryptococcus albidus 
Bipolaris eleusines Cryptococcus laurentii 
Cladosporium cladosporioides Cryptococcus neoformans 
Cladosporium oxysporum Cunninghamella bertholletiae 
Histoplasma capsulatum Geotrichum candidum 
Scedosporium prolificans Malassezia furfur 
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Table 2.2.1. (Continued) 
Reaction I Reaction II 
 Malassezia sympodialis 
 Mucor hiemalis 
 Mucor mucedo 
 Mucor racemosus 
 Rhizopus oryzae 
 Trichosporon asahii 
 Trichosporon cutaneum 
 Trichosporon inkin 
 Saccharomyces cerevisiae 
  
 Based on sequence alignments 
 Apophysomyces elegans 
 Basidiobolus ranarum 
 Cokeromyces recurvatus 
 Mucor circinelloides 
 Mucor ramosissimus 
 Mucor rouxii 
 Rhizomucor variabilis 
 Rhizopus azygosporus 
 Rhizopus microsporus 
 Rhizopus stolonifer 
 Rhodotorula mucilaginosa 
 Saksenaea vasiformis 
 Trichosporon asteroides 
 Trichosporon moniliiforme 
 Trichosporon mucoides 
 Trichosporon ovoides 
 
Human pathogenic fungi covered by the panfungal PCR detection assay including reactions 
I and II. 
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Table 2.2.2. Primers and probes used in the panfungal real-time PCR-assay 
 
Primer and probe sequences included in the panfungal PCR assay. Reaction I covers moulds 
and reaction II primarily yeasts and Zygomycetes. Nucleotides within brackets carry LNA 
modifications (22). 
a 











Reaction I Fw I TAAAGCTAAATAYYGGCCRGAGA 400 U28460 257-279 
  Rev I CT[T]TYCAAAGTGCTTTTCA[T]C 400 U28460 329-309 
       Z48339 277-255 
  Rev II CTCT[T]TTCAAAGTTCTTTTCA[T]C 400 U28460 331-309 
       Z48339 277-255 
 Probe I ACT[T]GT[G]CG[C]TA[T]CG 40 U28460 295-281 
      
Reaction II Fw I GGGTGGTRARYTCCWTCTAARGCTAA 400 Z48339 186-211 
  Fw II GGGWGGTAAATCYCWCCTAAAGCTAA 400 Z48339 186-211 
  Rev I CTCT[T]TYCAAAGTKCTTTTCA[T]C 400 U284460 329-309 
       Z48339 277-255 
 Probe II A[C]TT[G]T[T]C[G][C]TA[T]CG  50 Z48339 241-227 
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Table 2.2.3. Analysis of clinical specimens: training set 












































    1  2 11 10 
 
Abbreviations: Asp, Aspergillus, Can, Candida; EORTC, European Organization for Research and 
Treatment of Cancer 
Correlation of PCR results with clinical findings according to the EORTC criteria of IFD  
in the training cohort including febrile episodes in 43 patients.  
The cases of proven, probable and possible IFD revealed the presence of moulds (n=6; reaction I), 
yeasts/Zygomycetes (n=1; reaction II) or positivity in both reactions (n=3), respectively. Clinical 
assessment based on blood culture, HR-CT or histological analysis of targeted biopsies revealed 
findings indicative of Candida (Can) in one patient and Aspergillus (Asp) in 10 patients identified  
as having IFD according to the EORTC criteria. 
a 
EORTC negative indicates the lack of evidence for possible, probable, or proven IFD according  
to the consensus criteria. For these cases, the therapeutic (empirical) and prophylactic employment 
of antifungal agents as well as the absence of any administration of antifungals are indicated. 
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Table 2.2.4. Analysis of clinical specimens: validation set 
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Abbreviations: Asp, Aspergillus, Can, Candida; EORTC, European Organization for Research 
and Treatment of Cancer 
Correlation of PCR results with clinical findings according to the EORTC criteria of IFD  
in the validation cohort including 107 febrile episodes in 82 patients.  
The cases of proven, probable and possible IFD revealed the presence of moulds (n=10; 
reaction I), yeasts/Zygomycetes (n=1; reaction II) or positivity in both reactions (n=5), 
respectively. Clinical assessment based on blood culture, HR-CT or histological analysis  
of targeted biopsies revealed findings indicative of Candida (Can) in two patient and 
Aspergillus (Asp) in 14 patients identified as having IFD according to the EORTC criteria. 
a 
EORTC negative indicates the lack of evidence for possible, probable, or proven IFD 
according to the consensus criteria. For these cases, the therapeutic (empirical) and 
prophylactic employment of antifungal agents as well as the absence of any administration  





Panfungal detection reaction I 
 
Based on experimental evidence 
 
NCBI Acc.No Species             Position releated to A.fumigatus U28460 (1143906) 
                                232                                                                                              331 
AY567000    A.strictum          CTCTAAATGGGAGGTGTACGTCTTCTAAAGCTAAATACCGGCCAGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
AB100675    A.alternata         CTCTAAATGGGAGGTACATTTCTTCTAAAGCTAAATATTGGCCAGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGGAAAGAG 
U28763      A.candidus          CTCTAAATGGGTGGTAAATTTCATCTAAAGCTAAATATTGGCCGGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
AY216667    A.clavatus          CTCTAAATGGGTGGTAAATTTCATCTAAAGCTAAATACTGGCCGGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
U28889      A.flavus            CTCTAAATGGGTGGTAAATTTCATCTAAAGCTAAATACTGGCCGGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
U28460      A.fumigatus         CTCTAAATGGGTGGTAAATTTCATCTAAAGCTAAATACTGGCCGGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
U29859      A.nidulans*         CTCTAAATGGGTGGTAAATTTCATCTAAAGCTAAATACCGGCCGGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
U28817      A.niger             CTCTAAATGGGTGGTAAATTTCATCTAAAGCTAAATACTGGCCGGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
U28845      A.terreus           CTCTAAATGGGTGGTAAATTTCATCTAAAGCTAAATACTGGCCGGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
AF454195    A.versicolor        CTCTAAATGGGTGGTAAATTTCATCTAAAGCTAAATACCGGCCGGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
AF130373    F.oxysporum         CTCTAAATGGGAGGTATATGTCTTCTAAAGCTAAATACCGGCCAGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
Y07991      F.oxysporum         CTCTAAATGGA--GTATATGTC-TCTAAAGCTAAATACCGTCCAGAGACCGATAGCGCACAAGTA--GTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
AJ271213    F.proliferatum      CTCTAAATGGGAGGTATATGTCTTCTAAAGCTAAATACCGGCCAGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
AY097318    F.solani            CTCTAAATGGGAGGTATATGTCTTCTAAAGCTAAATACCGGCCAGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGAACTTTGAAAAGAG 
U34526      F.verticillioides   CTCTAAATGGGAGGTATATGTCTTCTAAAGCTAAATACCGGCCAGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
U15475      P.chrysogenum       CTCTAAATGGGTGGTAAATTTCATCTAAAGCTAAATATTGGCCGGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
AY213623    S.apiospermum*      CTCAAAATGGGAGGTAAACCCCTTCTAAAGCTAAATACTGGCCAGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
 
Based on sequence alignment 
 
AF433088    A.ochraceus         CTCTAAATGGGTGGTAAATTTCATCTAAAGCTAAATACTGGCCGGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
U81265      A.penicillioides    CTCTAAATGGGTGGTAAATTTCATCTAAAGCTAAATACTGGCCGGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
U81264      A.penicillioides    CTCTAAATGGGTGGTAAATTTCATCTAAAGCTAAATACAGGCCGGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
U29791      A.ustus             CTCTAAATGGGTGGTAAATTTCATCTAAAGCTAAATACCGGCCGGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
AF163994    B.eleusines         CTCTAAATGGGAGGTAAATTTCTTCTAAAGCTAAATATTGGCCAGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGGAAAGAG 
AY342114    C.cladosporioides   CTCTAAATGGGAGGTAAATTTCTTCTAAAGCTAAATATTGGCCAGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGGAAAGAG 
AY342116    C.oxysporum         CTCTAAATGGGAGGTAAATTTCTTCTAAAGCTAAATATTGGCCAGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGGAAAGAG 
AF071950    H.capsulatum*       CTCCAAATGGGTGGTAAATTTCATCTAAAGCTAAATACTGGTCGGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
AF027679    S.proliferans       CNCAAAATGGGAGGTAAACCCCTTCTAAAGCTAAATATTGGCCAGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGAAAAGAG 
 
M11167      Human 28S rRNA gene CCCAAAGCGGGTGGTAAACTCCATCTAAGGCTAAATACCGGCACGAGACCGATAGTCAACAAGTACCGTAAGGGAAAGTTGAAAAGAACTTTGAAGAGAG 
U13369      Human ribosomal DNA CCCAAAGCGGGTGGTAAACTCCATCTAAGGCTAAATACCGGCACGAGACCGATAGTCAACAAGTACCGTAAGGGAAAGTTGAAAAGAACTTTGAAGAGAG 
                                                         257                 279 281         295           309               329 
Oligonucleotide sequences                                TAAAGCTAAATAYYGGCCRGAGA GC9AT7GC8TG9TCA           C9ACTTTTCGTGAAACYT9TC 
for the detection reaction I                             5’                    3’3’            5’          3’                  5’ 
                                                            forward primer I          probe I                 reverse primer I 
                                                                                    (reverse)              309                 331 
                                                                                                           CXACTTTTCWTGAAACTT9TCTC 
                                                                                                         3’                      5’ 







Panfungal detection reaction II 
 
Based on experimental evidence 
 
NCBI Acc.No Species             Position releated to C.albicans Z48339 (671813) 
                                178                                                                                              277 
AF113446    A.corymbifera       CCTAAAGCTGGTGGTAAATCCCACCTAAAGCTAAATACAGGCGAGAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGAACTTTGAAAAGAG 
AF113445    A.corymbifera       CCTAAAGCTGGTGGTAAATCCCACCTAAAGCTAAATACAGGCGAGAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGTACTTTGAAAAGAG 
AB083084    B.capitatus*        CTC-AAATAGGTGGTAAACTCCATCTAAAGCTAAATATTGCTGGGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGCACTTTGAAAAGAG 
Z48339      C.albicans          CTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGAACTTTGAAAAGAG 
AB041003    C.allociferrii      CTCTAAGTGGGTGGTAAATTCCATCTAAGGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGAACTTTGAAAAGAG 
U72156      C.colliculosa*      CTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGAACTTTGAAAAGAG 
U45823      C.cylindracea       CTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGAACTTTGAAAAGAG 
U57685      C.dubliniensis      CTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGAACTTTGAAAAGAG 
AJ786242    C.famata*           CTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGAACTTTGAAAAGAG 
U44808      C.glabrata          CTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATACAGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGAACTTTGAAAAGAG 
AF374616    C.guilliermondii*   CTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGAACTTTGAAAAGAG 
U71062      C.inconspicua       CTCTAAGTGGGTGGTAAATTCCATCTAAGGCTAAATACTGGCGAGAGACCGATAGCGAACAAGTACTGTGAAGGAAAGATGAAAAGCACTTTGAAAAGAG 
AF335978    C.kefyr*            CTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGAACTTTGAAAAGAG 
U76347      C.krusei*           CTCCAAGCGGGTGGTAAATTCCATCTAAGGCTAAATACTGGCGAGAGACCGATAGCGAACAAGTACTGTGAAGGAAAGATGAAAAGCACTTTGAAAAGAG 
U75726      C.lambica*          CTCTAAGCGGGTGGTAAATTCCATCTAAGGCTAAATACTGGCGAGAGACCGATAGCGAACAAGTACTGTGAAGGAAAGATGAAAAGCACTTTGAAAAGAG 
AF020437    C.lambica*          CTCAAAGTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGAACTTTGAAAAGAG 
AF335977    C.lipolytica*       CTCAAAGTGGGTGGTAAACTCCATCTAAAGCTAAATACTGGTGAGAGACCGATAGCGAACAAGTACTGTGAAGGAAAGGTGAAAAGAACTTTGAAAAGAG 
U44817      C.lusitaniae*       CTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGCACTTTGAAAAGAG 
AJ539358    C.membranaefaciens  CTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACTGTGAAGGAAAGATGAAAAGAACTTTGAAAAGAG 
Z48568      C.norvegensis*      CTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGAACTTTGAAAAGAG 
U75730      C.norvegensis*      CTCTAAGCGGGTGGTAAATTCCATCTAAGGCTAAATACTGGCGAGAGACCGATAGCGAACAAGTACTGTGAAGGAAAGATGAAAAGCACTTTGAAAAGAG 
AF374609    C.parapsilosis      CTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGAACTTTGAAAAGAG 
AB126677    C.pelicullosa*      CTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGAACTTTGAAAAGAG 
AF374612    C.rugosa            CTCCAAGTGGGTGGTAAATTCCATCTAAAGCTAAATACTGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGCACTTTGAAAAGAG 
AJ507662    C.sake              CTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGAACTTTGAAAAGAG 
AF267497    C.tropicalis        CTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGAACTTTGAAAAGAG 
U73570      C.utilis*           CTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGAACTTTGAAAAGAG 
U45853      C.zeylanoides*      CTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGAACTTTGAAAAGAG 
AY296054    C.albidus           CTCAAAATGGGTGGTGAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGCACTTTGGAAAGAG 
AY315663    C.laurentii         CTCAAAATGGGTGGTGAGTTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGCACTTTGGAAAGAG 
L14067      C.neoformans*       CGCAAAATGGGTGGTAAACTCCATCTAAGGCTAAATATTGGTGGAAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGCACTTTGGAAAGAG 
AF335984    C.neoformans*       CGCAAAATGGGTGGTAAACTCCATCTAAAGCTAAATATTGGTGGAAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGCACTTTGGAAAGAG 
AF113459    C.bertholletiae     CCTAAAATGGGAGGTAAATCTCTCCTAAAGCTAAATATTGACGAAAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGCACTTTGAAAAGAG 
U40118      G.candidum          CTCTAAGTGGGAGGTAAATTCCTTCTAAAGCTAAATATTGACGAGAGACCGATAGCGAACAAGTACTGTGAAGGAAAGATGAAAAGCACTTTGAAAAGAG 
AF063214    M.furfur            CTCAAAATGGGTGGTAGACTCCATCTAAAGCTAAATATCGGGGAGAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGCACTTTGGAAAGAG 
AY743628    M.sympodialis       CTCAAAATGGGTGGTAGACTCCATCTAAAGCTAAATATCGGGGAGAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGCACTTTGGAAAGAG 
AF113468    M.hiemalis          CCTAAATTGGGTGGTAAATCTCACCTAAAGCTAAATATTTGCGAGAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGAACTTTGAAAAGAG 
AY706243    M.hiemalis          CCTAAAATGGGAGGTAGACTTCTCCTAAAGCTAAATATTGACGAAAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGCACTTTGAAAAGAG 
AF113470    M.mucedo            CCTAAATTGGGTGGTAAATCTCACCTAAAGCTAAATATTTGCGAGAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGAACTTTGAAAAGAG 
 
 






Based on sequence alignment 
 
AF113471    M.racemosus*        CCTAAATTGGGTGGTAAATCTCACCTAAAGCTAAATATTTGCGAGAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGAACTTTGAAAAGAG 
AF105396    T.inkin             CTCAAAATGGGTGGTGAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGCACTTTGGAAAGAG 
J01355      S.cerevisiae        CTCTAAGTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACAGTGATGGAAAGATGAAAAGAACTTTGAAAAGAG 
AY213625    R.oryzae            CCTAAATTGGGTGGTAAATCTCACCTAAAGCTAAATATTGGCGAGAAACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGAACTTTGAAAAGAG 
AF105393    T.asahii            CTCAAAATGGGTGGTGAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGCACTTTGGAAAGAG 
AJ749837    T.cutaneum          CTCAAAATGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGCACTTTGGAAAGAG 
AF113450    A.elegans           CCTTAATTGGGTGGTAAATCTCACCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGAACTTTGAAAAGAG 
AF113452    B.ranarum           CTCAAAATGGGTGGTAAATTTCATCTAAAGCTAAATATTGGCAAGAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGAACTTTGAAAAGAG 
AF113454    C.recurvatus        CCTAAATTGGGTGGTAAATCTCACCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGAACTTTGAAAAGAG 
AY213710    M.circinelloides    CCTAAATTGGGTGGTAAATCTCACCTAAAGCTAAATATTTGCGAGAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGAACTTTGAAAAGAG 
AF113472    M.ramosissimus      CCTAAATTGGGTGGTAAATCTCACCTAAAGCTAAATATTTGCGAGAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGAACTTTGAAAAGAG 
AF157174    M.rouxii*           CCTAAATTGGGTGGTAAATCTCACCTAAAGCTAAATATTGGCGAGAAACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGAACTTTGAAAAGAG 
AF113476    R.variabilis        CCTAAATTGGGTGGTAAATCTCACCTAAAGCTAAATATTTGCGAGAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGAACTTTGAAAAGAG 
AF113477    R.azygosporus       CCTAAATTGGGTGGTAAATCTCACCTAAAGCTAAATATTGGCGAGAAACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGAACTTTGAAAAGAG 
AF113480    R.microsporus       CCTAAATTGGGTGGTAAATCTCACCTAAAGCTAAATATTGGCGAGAAACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGAACTTTGAAAAGAG 
AF113479    R.microsporus       CCTAAATTGGGTGGTAAATCTCACATAAAGCTAAATATTGGCGAGAAACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGAACTTTGAAAAGAG 
AF113482    R.stolonifer        CCTAAATTGGGTGGTAAATCTCACCTAAAGCTAAATATTGGCGAGAAACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGAACTTTGAAAAGAG 
AF485994    R.mucilaginosa      CTCAAATTGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGCACTTTGGAAAGAG 
AF113483    S.vasiformis        CCTTAATTGGGTGGTAAATCTCACCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGAACTCTGAAAAGAG 
AF075513    T.asteroides        CTCAAAATGGGTGGTGAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGCACTTTGGAAAGAG 
AF444719    T.moniliiforme      CTCAAAATGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGCACTTTGGAAAGAG 
AF335988    T.mucoides          CTCAAAATGGGTGGTAAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGCACTTTGGAAAGAG 
AF075523    T.ovoides           CTCAAAATGGGTGGTGAATTCCATCTAAAGCTAAATATTGGCGAGAGACCGATAGCGAACAAGTACCGTGAGGGAAAGATGAAAAGCACTTTGGAAAGAG 
 
M1167       Human 28S rRNA gene CCCAAAGCGGGTGGTAAACTCCATCTAAGGCTAAATACCGGCACGAGACCGATAGTCAACAAGTACCGTAAGGGAAAGTTGAAAAGAACTTTGAAGAGAG 
U13369      Human ribosomal DNA CCCAAAGCGGGTGGTAAACTCCATCTAAGGCTAAATACCGGCACGAGACCGATAGTCAACAAGTACCGTAAGGGAAAGTTGAAAAGAACTTTGAAGAGAG 
                                        186                    211               227         241             255                 277 
Oligonucleotide sequences               GGGTGGTRARYTCCWTCTAARGCTAA               GC9AT78C9T8TT7A             C9ACTTTTCKTGAAACYT9TCTC 
for the detection reaction II           5’                       3’              3’            5’            3’                    5’ 
                                             forward primer I                         probe II                   reverse primer I 
                                        186                    211                  (reverse)    
                                        GGGWGGTAAATCYCWCCTAAAGCTAA             
                                        5’                       3’        




Wobble positions used: R = G or A; W = A or T; Y = C or T; K = G or T 










* Species listed under other name in the NCBI database: Aspergillus nidulans = NCBI Emericella nidulans, 
Scedosporium apiospermum = NCBI Pseudallescheria boydii, Histoplasma capsulatum = NCBI Ajellomyces capsulatus, 
Candida colliculosa = NCBI Torulaspora delbrueckii, Candida famata = NCBI Debaryomyces hansenii, Candida 
guilliermondii = NCBI Pichia guilliermondii, Candida kefyr = NCBI Kluyveromyces marxianus, Candida krusei = NCBI 
Issatschenkia orientalis, Candida lambica = NCBI Pichia fermentas, Candida lipolytica = NCBI Yarrowia 
lipolytica, Candida lusitaniae = NCBI Clavispora lusitaniae, Candida norvegensis = NCBI Pichia norvegensis, 
Candida pelliculosa = NCBI Pichia anomala, Candida utilis = NCBI Pichia jadinii, Candida zeylanoides = NCBI 
Candida krissii, Blastoschizomyces capitatus = Dipodascus capitatus, Cryptococcus neoformans = NCBI 
Filobasidiella naoformans, Mucor racemosus = NCBI Rhizomucor racemosus, Mucor rouxii = NCBI Amylomyces rouxii, 
Geotrichum candidum = NCBI Galactomyces geotrichum 
 
 
Figure 2.2.1. (Continued) Multiple sequence alignment (Corpet F, 1988) of the highly conserved 28S rDNA gene 
region selected for a design of the panfungal detection system. About 90 different sequences accessible  
on the NCBI database were aligned including a variety of mould-, yeast- and the corresponding human 
sequences. Two RQ-PCR assays were designed to cover the indicated spectrum of fungal species. Detection 
reaction I covers moulds (21 isolates/strains tested experimentally and 8 species based on the sequence 
alignment) and detection reaction II covers primarily yeasts and Zygomycetes (42 isolates/strains tested 
experimentally and 16 species based on sequence alignment). The primer pairs and the probes (grey boxes) were 
placed within the target region. The indicated nucleotide positions refer to the sequences of A. fumigatus (NCBI 
accession no. U28460) for reaction I and C.albicans (NCBI accession no. Z48339) for reaction II, respectively.  
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ΔRn is the difference between emission intensity of reporter day in PCR with template and emission 
intensity of reporter day in PCR without template or in early cycles of a real-time reaction related  
to emission intensity of passive refference day 
CT threshold cycle is the number of cycles at which the fluorescence exceeds the threshold 
 
Figure 2.2.2. Amplification plots (a, b) and standard curves (c, d) for quantitative fungus 
analysis by the panfungal detection system. The upper panels show amplification plots  
of serial logarithmic dilutions of fungal gDNA (ranging from 10 fg to 100 pg) derived  
from A.fumigatus (a) amplified by the panfungal detection reaction I and C.albicans (b) 
amplified by the panfungal detection reaction II. The lower panels (c, d) reveal  
the corresponding standard curves generated on the basis of the amplification profiles 
displayed. The assays underlying the generation of standard curves were performed  
in duplicates. The Y-intercept, which corresponds to the theoretical limit of detection, was 
determined at CT 39,9 for reaction I and CT 37,8 for reaction II. In view of the great 
similarity between the amplification profiles of all fungal species covered by the panfungal 
assay, the standard curves shown are applicable to the quantification of any Candida, 
Aspergillus and other fungal species detected. 
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2.3  Identification of fungal species by fragment length analysis 
of the internally transcribed spacer 2 region 
 
2.3.1 AIM OF THE STUDY 
 
The rapid identification of fungal pathogens in clinical specimens is a prerequisite  
for timely onset of the most appropriate treatment. The aim of the present study was 
to develop a sensitive method facilitating the identification of a broad spectrum  
of fungal species with a detection limit adequate for routine clinical diagnosis of IFDs 
in immunosuppressed individuals. The intended clinical application of the technique 
is the rapid identification of fungal species in clinical specimens that have been 
previously shown to be positive for fungal DNA by a broad-spectrum screening 
technique not capable of identifying the fungal species. 
 
 
2.3.2 MATERIALS AND METHODS 
 
2.3.2.1 Fungal strains, bacteria, and viral isolates 
 
The fungal reference strains tested were obtained from the ATCC (Rockville, USA), 
the DSM (Braunschweig, Germany), the IHMM, (Medical University of Vienna, 
Austria), and from the Faculty of Medicine, Charles University (FMCU), (Hradec 
Kralove, Czech Republic). All fungal strains were grown on Sabouraud dextrose 
agar, yeasts at 37°C (Cryptococcus spp. at 30°C) for 48 h and moulds at 30°C  
for one to seven days until sporulation. Yeast identification was performed by ID32 C 
test (BioMerieux, Marcy I’Etoile, France) and by micromorphology on rice-agar. 
Moulds were identified based on conventional macro- and microscopic 
morphological investigation. The reference strains are indicated in Table 2.3.1.  
In addition, a panel of bacterial and viral microorganisms was selected for testing 
of cross-reactivity as indicated in Baskova et al. 2007.  
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2.3.2.2 Clinical materials 
 
Fungus-positive clinical specimens including biopsies of pulmonary infiltrations, 
bronchotracheal secretions, peripheral blood, cerebrospinal fluid, and plasma were 
obtained from the St. Anna Children’s Hospital, Vienna, Austria and from  
the Division of Clinical Microbiology, IHMM, Medical University of Vienna. Ocular 
specimens from patients with eye infections were provided by the FMCU, Hradec 
Kralove, Czech Republic. All clinical specimens were obtained from the patients 
after informed consent. Peripheral blood specimens from healthy volunteer donors 
were used as negative controls. 
 
 
2.3.2.3 DNA extraction 
 
The isolation and purification of DNA from fungal strains, as well as of fungal human, 
bacterial and viral DNA from different clinical materials was performed essentially  
as described earlier (Baskova et al. 2007).  
 
 
a) Plasma containing white blood cells 
 
Peripheral blood specimens anticoagulated with EDTA were kept at 4°C for at least 
4 h to sediment the red blood cells. The entire supernatant, i. e. plasma containing 
white blood cells, was used for DNA extraction. The samples were centrifuged  
at 15.000 g for 10 min. Most of the supernatant was removed, leaving a residual 
volume of 100 µl, and 430 µl of LLB was added. The DNA extraction from other 
clinical materials was performed as described by Baskova et al. 2007. 
 
b) Cerebrospinal fluid 
 
The samples were centrifuged at 15.000 g for 10 min. Most of the supernatant was 
removed, leaving a residual volume of 100 µl, and 430 µl of LLB was added.  
The DNA extraction was performed as described above.  
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2.3.2.4 PCR amplification 
 
a) First amplification round 
 
The universal primers, ITS4 reverse primer (Turenne et al. 1999) (5’-TCC TCC GCT 
TAT TGA TAT GCT-3’) and a newly designed forward primer (5’-TTT CAA CAA 
YGG ATC TCT TGG-3’), which we have termed ITS7 were used to amplify across 
the entire ITS1, 5.8S, ITS2, and part of the 18S and 28S regions of the rDNA gene. 
The 25 l PCR reaction mix contained GeneAmpR 1 x PCR buffer II  
(AB, Branchburg, New Jersey, USA), 2.5 mM MgCl2 (AB), 200 µM deoxynucleotide 
triphosphates (dNTPs), dATP, dCTP, dGTP, and a 1:8 ratio of dUTP to dTTP 
(Invitrogen), 400 nM of each primer, 0.25 U heat-labile UNG (Hoffmann-La Roche 
Ltd, Basel, Switzerland), 2.5 U AmpliTaq® DNA Polymerase (AB), molecular biology 
grade water (Eppendorf, Hamburg, Germany) and 5 l template DNA. The PCR was 
performed according to the following protocol: 10 min at 37°C (UNG activation),  
10 min at 95°C (polymerase activation) and 35 cycles of 95°C for 30 s, 55°C  
for 1 min, 72°C for 50 s, and a final extension step at 60°C for 45 min, followed  
by cooling to 4°C (Longo et al. 1990).  
 
 
b) Second amplification round 
 
The primer used included the reverse primer ITS4 (sequence indicated above) and 
two fluorescein-labeled forward primers ITS86-I (5’-TGA ATC ATC GAR TCT TTG 
AAC G-3’) and ITS86-II (5’-TGA ATC ATC GAG TTC TTG AAC G-3’), which 
hybridize to the 5.8S region of the rRNA gene. The PCR reaction mix contained 3 µl 
of the first round PCR product, GeneAmpR 1x PCR buffer II (AB), 2.5 mM MgCl2 
(AB), 200 µM dNTPs (including dUTP), 400 nM of each primer and 1 U of AmpliTaq® 
DNA Polymerase (AB) in a total volume of 25 µl. The amplification conditions were 
identical to the first round of amplification, with omission of the initial UDG activation 
step. In laboratories less experienced with PCR work, the risk of contamination 
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inherent in nested PCR approaches can be reduced e.g. by adapting a single-tube 
two-round PCR technique described earlier (Trka et al. 1995). 
 
 
2.3.2.5 Fragment analysis by capillary electrophoresis 
 
Fragment analysis was performed on the ABI PRISM 3100-Avant (AB) genetic 
analyzer, an automated fluorescence capillary electrophoresis system. The set-up  
of the instrument was done according to the manufacture’s instructions. Due  
to the fluorescein label of the ITS86 primers, the matrix kit PowerPlex® Matrix 
Standards, 3100 (Promega, Mannheim, Germany) was used to establish a matrix file 
(dyset Z). Analysis parameters and length standards were established according  
to the PowerPlex 16 System technical manual (Promega). 1 µl of the PCR product 
generated by semi-nested PCR amplification was mixed with 1 µl of the internal 
length standard ILS 600 (Promega) and 24 µl deionized formamide HiDi (AB). After 
denaturation for 3 min at 94°C and cooling to 4°C, the whole sample was injected 
into a 36 cm capillary column containing the high performance polymer POP-4TM 
(AB). Electrophoresis parameters on the ABI PRISM 3100-Avant were set at 15 s 
injection time, 3 kV injection voltage, 15 kV electrophoresis voltage, and an oven 
temperature of 60°C. The average electrophoresis time was 30 min to permit 
detection of PCR fragments up to 500 nt in length. PCR product lengths were 
analyzed using the ABI PRISM GeneScan Analysis software 3.7 (AB). Signals 
were regarded as positive if the fluorescence intensity was higher than 50 reference 
fluorescence units (RFUs). 
A number of precautions were undertaken to control the occurrence of false 
positive results. Multiple no-template and non-homologous template controls were 




2.3.3.1 Analysis of fungal reference strains 
 
To determine the ability of the technique presented to identify a broad spectrum  
of human pathogenic fungi, a total of 96 reference strains derived from 60 different 
fungal species were analyzed by the semi-nested pan-fungal PCR amplification 
followed by capillary electrophoresis (Table 2.3.1). The most common strains are 
indicated in Table 2.3.1. Upon comprehensive sequence alignment of the targeted 
ITS2 region from all fungal isolates represented in the GenBank database, minor 
intra-species variations became apparent. However, when testing multiple isolates 
per fungal species, which were obtained from different sources, the ITS2 sizes 
observed corresponded well with those of the reference strains displayed  
in Table 2.3.1 (data not shown).  
To verify the morphological classification of the fungal reference strains,  
the PCR products of each strain were sequenced and compared to the GenBank 
entries. In some instances, the sequence analysis data differed from the species 
designation provided by the supplier (the sequence of Malassezia furfur DSM 6171 
corresponded with that of Malassezia sympodialis in the GenBank database, and  
the sequence of C. sake DSM 70763 with C. oleophila). The ITS2 amplicon length  
of all reference strains was determined by two independent PCR assays followed  
by four separate runs of capillary electrophoresis on the ABI PRISM 3100 genetic 
analyzer. From these measurements, the mean ITS2 fragment length was calculated 
for every fungal strain tested. Under standardized conditions, the run-to-run variation 
between amplicon size measurements revealed a 95% confidence interval  
of 0.7 nucleotide(s) (nt) in the case of A. terreus DSM 1958 (Table 2.3.1), thus 
demonstrating the high reproducibility of PCR amplicon size analysis. Unequivocal 
identification of individual fungal strains was possible in most instances, but certain 
limitations of the technology have become apparent, as discussed below. The sizes 
of ITS2 amplicons were in a range between 184 nt (C. lipolytica) and 381 nt (Absidia 
corymbifera) (Table 2.3.1). 
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The specificity of the assay for the detection of fungal target sequences was 
assessed by testing human genomic DNA extracted from peripheral blood  
of voluntary healthy donors and different viral and bacterial strains (see Materials 
and Methods). No cross-reactivity of the amplification and detection system  
with non-fungal targets has been observed (data not shown). 
 
 
2.3.3.2 Sensitivity of the assay 
 
The limit of detection was determined by testing serial dilutions of genomic fungal 
DNA derived from A. fumigatus and C. albicans as representatives of moulds and 
yeasts, respectively. Template DNA ranging from 1 fg to 1 pg was amplified  
by the semi-nested PCR protocol and products were evaluated on the ABI PRISM 
3100 genetic analyzer. The reproducible detection limit of capillary electrophoresis 
after semi-nested PCR amplification was 1 fg for both fungal strains tested  
(Figure 2.3.1), which is equivalent to a fraction of a single fungal genome  
on the basis of the estimated genome mass of 32 fg for Aspergillus species, and  
37 fg for Candida species. 
 
 
2.3.3.3 Assessment of clinical applicability 
 
To assess the ability of the assay to facilitate identification of specific fungal 
pathogens in the clinical setting, different types of specimens collected from  
26 patients with documented fungal infection were investigated. The specimens 
tested included peripheral blood, plasma, cerebrospinal fluid, ocular specimens, 
secretions from the respiratory tract, and lung biopsies. Extraction of fungal DNA, 
pan-fungal semi-nested PCR amplification, and analysis of the ITS2 fragments  
by capillary electrophoresis were performed as described above. In order to ensure 
the absence of cross-reactivity with human DNA or the occurrence of external 
contamination, DNA from whole blood of healthy volunteer donors was extracted 
and analyzed in parallel with the clinical specimens investigated (Figure 2.3.2, panel 
9). All clinical specimens studied were positive for fungal DNA by PCR analysis, and 
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the respective species were identified by comparing the ITS2 fragment sizes 
obtained by capillary electrophoresis to external reference standards (Table 2.3.1; 
Figure 2.3.2). The fungal species identified in the clinical specimens analyzed are 
listed in Table 2.3.2. The cerebrospinal fluid, peripheral blood and plasma samples 
tested revealed C. albicans, C. glabrata, and A. flavus/A. niger, respectively.  
The lung biopsies showed infections by A. fumigatus and C. lipolytica. The secretion 
samples from the respiratory tract tested positive for A. fumigatus in most instances 
and for Rhizopus oryzae on a single occasion. In one of the respiratory secretion 
specimens, a mixed infection with A. fumigatus and C. albicans was identified. All 
ocular specimens investigated revealed an infection by Fusarium oxysporum, 
caused by a point source outbreak in the hospital ward from which all these 
specimens were derived. Examples of ITS2 PCR fragments representing different 
fungal pathogens detected in the clinical samples investigated are displayed  
in Figure 2.3.2. Since certain strains of A. flavus and A. niger showed nearly 
identical sizes of ITS2 PCR amplicons upon capillary electrophoresis, unambiguous 
identification of the pathogen present was achieved by subsequent sequencing.  
In all instances, PCR positive results were confirmed by an independent technique, 






We have established a semi-nested PCR technique for amplification of the variable 
ITS2 region from the multi-copy ribosomal rRNA gene coupled with automated 
fragment length analysis to facilitate rapid species-specific identification of a large 
spectrum of clinically relevant fungal pathogens. The technique presented was 
specifically designed to permit identification of the fungal species in any clinical 
specimen previously shown to be positive for fungal DNA by a broad-spectrum 
amplification assay lacking the ability of species recognition (Klingspor and Jalal 
2006; Basková et al. 2007; Costa et al. 2002; Maaroufi et al. 2004; White et al. 
2003). Several PCR-based methods for species-specific identification exploit  
79 
the sequence variability of the ITS2 region, which is flanked by conserved 
sequences of the rRNA gene (Martin et al. 2000; Elie et al. 1998; Yamakami et al. 
1996; Einsele et al. 1997; van Burik et al. 1998; Sandhu et al. 1995).  
The identification of cultured fungal strains by ITS2 fragment length analysis has 
been described previously (Chen et al. 2000; Turenne et al. 1999; Williams et al. 
1995). However, the achievable detection limit of these approaches could render  
the detection of IFDs in routine clinical diagnosis difficult, because the concentration 
of fungal pathogens in specimens, such as peripheral blood, is generally very low 
(Loeffler et al. 2000). It is important to consider that in immunosuppressed patients 
the presence of fungal pathogens, even at extremely low concentrations, may reflect 
a life-threatening infection. We have established a pan-fungal semi-nested PCR 
protocol for efficient amplification of the fungal ITS2 regions using a newly designed 
and optimized forward primer for the first round of amplification. Our modification  
of the detection system based on the semi-nested amplification of the ITS2 region 
facilitates highly sensitive species identification, which renders the technique 
suitable for clinical application, especially in immunocompromised patients where 
conventional diagnostic methods often fail owing to low sensitivity or specificity.  
The lowest amount of fungal genomic DNA permitting consistent species recognition 
by the approach presented was 1 fg, which is equivalent to a fraction of a single 
fungal organism on the basis of the estimated genome mass (Aspergillus 32 fg, and 
Candida 37 fg) (Figure 2.3.1). 
The PCR fragment lengths determined by capillary electrophoresis differed 
from those expected on the basis of sequence analysis and from previously 
published data (De Baere et al. 2002; Turenne et al. 1999). This divergence can be 
attributed primarily to the specific properties of the capillary electrophoresis 
apparatus used and to migration shifts during electrophoresis caused  
by the fluorescent dye component. Potential sources of intrinsic variability  
of fragment size measurements were compensated for by implementing an internal 
laboratory reference panel of well defined fungal strains. The method presented not 
only permits the identification of almost all clinically relevant species from the genera 
Aspergillus and Candida, which still account for the vast majority of IFDs, but also 
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facilitates the identification of a large panel of emerging fungal species, such  
as Fusarium, Trichosporon, or Zygomycetes. The ability to identify a broad spectrum 
of fungal pathogens is essential with regard to the changing epidemiology  
of invasive mycoses and differences in the susceptibility pattern of individual fungal 
species to conventional and new antifungal agents. 
Of the clinical samples analyzed, ITS2 fragment length analysis permitted 
unequivocal identification of the fungal species in all specimens, with a single 
exception (Figure 2.3.2) attributable to the fact that some fungal species have similar 
or identical ITS2 fragment sizes (Table 2.3.1). From the perspective of optimal 
choice of treatment, the discrimination between pathogens is particularly important  
in instances in which the suspected fungal species require different antimycotic 
therapy (Slavin et al. 2004). Some pathogens, such as A. flavus (DSM818) and  
A. niger (ATCC10535, DSM737), which display similar ITS2 fragment sizes, share 
the susceptibility to identical antifungal agents, thus rendering unequivocal 
identification of the species less important (Mallié et al. 2005). Some other species 
that cannot be clearly discriminated by ITS2 fragment length analysis are, however, 
susceptible to different antifungal agents. This applies to C. dubliniensis (ATCC 
MYA-646) and C. krusei (IHMM, DSM 70075), the latter of which is intrinsically 
resistant to fluconazole (Messer et al. 2006), to A.terreus and Trichosporon spp., 
and to Acremonium strictum and A. terreus. In these instances, the analysis  
of reference fungal strains in the same run can be helpful in discriminating between 
the fungal species. Additionally, alternative methods, such as sequencing  
of the PCR product or restriction fragment length polymorphism (RFLP) analysis 
(Dendis et al 2003; Trost et al. 2004) may be instrumental in facilitating unequivocal 
identification of the fungal species present and permit the administration of adequate 
antifungal therapy. 
A limitation of ITS2 fragment length analysis is the potential occurrence  
of intra-species variations of ITS2 fragment sizes in clinical isolates which do not 
correspond to the ITS2 sizes of the defined fungal strains presented in the reference 
panel. The testing of multiple isolates derived from the fungal species of interest 
revealed ITS2 sizes which correlated very well with those presented in Table 2.3.1. 
81 
Based on comprehensive ITS2 sequence alignments of clinical isolates represented 
in the GenBank database (up to 190 entries per species - in the case  
of Saccharomyces cerevisiae), the most common fragment sizes are indicated  
in the reference panel. However, it may be necessary to supplement or slightly 
modify the panel based on regional differences in the predominant occurrence  
or the emergence of certain fungal strains.  
An essential feature of the technique presented is the ability to detect  
co-infections with different fungi by revealing two or more amplification signals  
of different size in a single electropherogram (Figure 2.3.2, panel 5).  
The identification of co-infections with different fungal pathogens, which  
is not uncommon in immunocompromised individuals, is an important prerequisite 
for the most appropriate antifungal therapy. 
Our data demonstrate that fragment length analysis by capillary 
electrophoresis after semi-nested PCR amplification of the ITS2 region permits 
highly sensitive and reliable identification of a large panel of different potentially 
pathogenic fungi. The method is readily applicable in the routine laboratory practice 
and could contribute to successful management of IFDs. 
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Table 2.3.1. Mean fragment size (nt) with 95% confidence intervals of PCR 





Candida lipolytica DSM 8218 183,4 183,3-183,5 
Candida lipolytica IHMM 184,0 183,9-184,1 
Geotrichum candidum  DSM 1240 188,7 188,6-188,8 
Candida lusitaniae DSM  70102 196,3 196,2-196,4 
Candida lusitaniae IHMM 196,6 196,4-196,8 
Candida pararugosa IHMM 214,2 213,9-214,5 
Candida rugosa FMCU 214,3 214,2-214,4 
Candida lambica DSM 70090 241,3 240,7-241,9 
Candida lambica IHMM 243,1 242,7-243,5 
Blastoschizomyces capitatus IHMM 245,6 245,5-245,7 
Candida parapsilosis ATCC 22019 249,5 249,3-249,7 
Candida parapsilosis IHMM 249,6 249,4-249,8 
Candida parapsilosis DSM 11224 249,6 249,4-249,8 
Candida norvegensis FMCU 262,7 262,5-262,9 
Candida norvegensis DSMZ 70760 264,9 264,8-265,0 
Candida tropicalis DSM 5991 266,1 266,0-266,2 
Candida valid IHMM 266,3 266,3 
Candida  inconspicua DSM 70631 266,6 266,5-266,7 
Candida tropicalis ATCC 750 266,8 266,7-266,9 
Fusarium oxysporum DSM 2018 273,9 273,8-274,0 
Fusarium verticilloides DSM 62264 275,5 275,3-275,7 
Candida albicans DSM 1386 277,5 277,5 
Candida albicans IHMM 277,7 277,6-277,8 
Candida dubliniensis IHMM 280,2 280,2 
Candida krusei  ATCC 6258 281,6 281,4-281,8 
Candida krusei  IHMM 282,1* 281,7-282,5 
Candida dubliniensis ATCC MYA-646 282,3* 282,2-282,4 
Candida krusei  DSM 70075 282,3* 282,1-282,5 
Aspergillus candidus IHMM 283,6 283,5-283,7 
Aspergillus candidus DSM 814 283,8 283,5-284,1 
Alternaria alternata DSM 62006 284,0 283,7-284,3 
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Fusarium proliferatum DSM 840 284,9 284,8-285,0 
Fusarium proliferatum IHMM 284,9 284,8-285,0 
Aspergillus fumigatus ATCC 36607 285,5 285,0-286,0 
Aspergillus fumigatus DSM  819 285,5 285,2-285,8 
Aspergillus fumigatus IHMM 285,7 285,4-286,0 
Aspergillus nidulans DSM 946 285,9* 285,3-286,4 
Aspergillus versicolor IHMM 286,3 286,2-286,4 
Aspergillus nidulans DSM 820 286,3* 286,2-286,4 
Aspergillus nidulans IHMM 286,4* 286,2-286,6 
Aspergillus clavatus DSM 816 286,5* 285,9-287,1 
Aspergillus clavatus IHMM 286,8 286,7-286,9 
Aspergillus versicolor DSM 1943 287,7 287,4-288,0 
Fusarium solani DSM 62413 288,3 288,1-288,5 
Aspergillus niger ATCC 10535 288,4* 288,1-288,7 
Aspergillus flavus DSM 818 288,5* 287,9-289,1 
Aspergillus niger DSM 737 288,9* 288,7-289,1 
Aspergillus glaucus IHMM 289,0* 289,0 
Aspergillus flavus IHMM 289,6 289,5-289,7 
Aspergillus niger IHMM 291,2* 290,9-291,5 
Acremonium strictum DSM 3567 294,5* 294,4-294,6 
Aspergillus terreus DSM 1958 294,7* 294,0-295,3 
Aspergillus terreus IHMM 295,0 294,9-295,1 
Cryptococcus humicolus FMCU 295,3 295,2-295,4 
Trichosporon inkin IHMM 295,6* 295,3-295,9 
Candida cylindracea DSM 2031 295,8* 295,4-296,2 
Aspergillus terreus DSM 826 295,8* 295,7-295,9 
Trichosporon beigelii IHMM 295,9* 295,8-296,0 
Trichosporon cutaneum DSM 70707 296,0* 295,9-296,1 
Trichosporon asahii IHMM 297,3 297,1-297,5 
Mucor hiemalis DSM 2656 301,2 301,0-301,4 
Candida utilis DSM 2361 303,2 303,1-303,3 
Cryptococcus laurentii IHMM 303,5 303,2-303,8 
Cryptococcus laurentii DSM 70766 304,8 304,7-304,9 
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Cunninghamella bertholletiae  IHMM 306,0 305,9-306,1 
Candida allociferii IHMM 306,5 306,4-306,6 
Mucor racemosus  DSM 62760 308,4 308,2-308,6 
Mucor rouxii DSM 1191 310,1 309,9-310,3 
Candida pelliculosa FMCU 311,1 310,9-311,3 
Cryptococcus neoformans DSM 70219 313,7 313,6-313,8 
Cryptococcus neoformans IHMM 313,7 313,6-313,8 
Candida zeylanoides DSM 70185 313,9 313,8-314,0 
Candida zeylanoides IHMM 313,9 313,8-314,0 
Candida pelliculosa DSM 70130 314,5* 314,4-314,6 
Candida sake DSM 70763
a
 314,5* 314,4-314,6 
Candida membranifaciens DSM 70109 315,7 315,6-315,8 
Rhizopus oryzae  DSM 853 316,2 316,2 
Rhizopus oryzae  IHMM 316,2 316,1-316,3 
Candida  guilliermondii DSM 70051 318,7 318,4-319,0 
Candida  guilliermondii DSM 11947 318,8 318,6-319,0 
Candida  guilliermondii IHMM 318,8 318,6-319,0 
Candida famata  IHMM 320,8 320,7-320,9 
Candida famata  DSM 70590 321,0 320,9-321,1 
Scedosporium apiospermum  ATCC 28206 321,7 321,4-322,0 
Mucor mucedo DSM 809 346,6 346,4-346,8 
Cryptococcus albidus DSM 70215 348,2 348,1-348,3 
Candida glabrata ATCC 2001 356,3 356,2-356,4 
Candida glabrata IHMM 358,3 358,2-358,4 
Candida glabrata DSM 1122  358,6 358,5-358,7 
Malassezia furfur DSM 6171
b
 359,2 359,2 
Saccharomyces cerevisiae  IHMM 362,0 361,9-362,1 
Saccharomyces cerevisiae  DSM 70449 362,9 362,6-363,2 
Candida kefyr  DSM 70073 371,0 370,8-371,2 
Candida kefyr  IHMM 371,0 370,9-371,1 
Absidia corymbifera  IHMM 380,8 380,5-381,1 




Table 2.3.1. (Continued) 
 
a
 Determined as Candida oleophila by sequence analysis 
b
 Determined as Malassezia sympodialis by sequence analysis 
 
It should be noted that the similarity of fragment sizes between individual fungal species,  
as indicated in the Table (
*
), may require further investigation (e.g. sequencing) to clearly 
identify the species present. In the setting of IFI, this may be relevant for species susceptible 
to different antifungal agents. 
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by ITS2 fragment 
length analysis 
Confirmation 
Bronchotracheal secretions (9) 285.2- 285.6 A. fumigatus culture 
Bronchotracheal secretion (1) 316.2 Rhizopus oryzae culture 
Bronchotracheal secretion (1) 277.5 C. albicans DNA hybridization  
culture   285.3 A. fumigatus 
Lung biopsy (1) 285.3 A. fumigatus DNA sequencing 
Lung biopsy (1) 184.1 C. lipolytica DNA sequencing 
Ocular specimens (10) 273.9 - 274.0 Fusarium oxysporum DNA sequencing, culture 
Peripheral blood (1) 358.1 C. glabrata culture 
Plasma (1) 288.5 A. flavus / A. niger DNA sequencing (A. flavus) 






Figure 1. Sensitivity assessment of fragment analysis. Serial dilutions  
of genomic DNA from A. fumigatus and C. albicans (1 pg, 100 fg, 10 fg, 1 fg 
and 0 fg) were used as templates for semi-nested PCR amplificationof the ITS2 
region. The PCR products were evaluated by capillary electrophoresis  




Figure 2.3.2. Examples of internally transcribed spacer 2 (ITS2) fragment length 
analysis of fungal pathogens detected in clinical specimens. The analysis was 
performed on the ABI PRISM ® 3100-Avant Genetic Analyzer. 
Electrophoreograms of eight clinical cases are presented. The fungal species 
were identified by comparison of the detected PCR fragment sizes  
with the external reference panel. Sample 9 is a negative control of amplification 




As a consequence of the growing number of immunocompromised patients and  
the expanding spectrum of newly emerging fungal species, opportunistic IFDs will 
continue to be a major cause of morbidity and mortality in this population. Early 
detection of IFD in high-risk patients is a prerequisite for rational and timely initiation 
of effective antifungal therapy. Conventional techniques display limited sensitivity 
and/or specifity in detecting systemic fungal infections, and the results are mostly 
available late in the course of infection. Recent advances in the development  
of non-invasive and culture-independent diagnostic techniques have led  
to significant improvement by facilitating earlier detection of IFD by incorporating 
biomarkers and molecular technique results into diagnostic algorithms (Ostrosky-
Zeichner 2012). 
Although antigen detection has shown variable performance in large clinical 
studies revealing both benefits and limitations, the availability of standardized 
protocols and quality assurance provided by commercial kits have allowed their 
inclusion in the diagnostic criteria for IFD established by the EORTC/MSG 
Consensus Group. The potential value of nucleic acid-based approaches  
to the detection and identification of fungal pathogens in immunocompromised 
patients is indisputable, as shown by a number of studies. To date, a large number 
of different molecular techniques have been published including different PCR 
approaches. However, the current lack of standardization and validation across  
a wide spectrum of diagnostic laboratories has prevented inclusion of these tests  
in the diagnostic criteria of IFD proposed by the EORTC/MSG Consensus Group. 
For clinical implementation of reliable and robust molecular methods, the laboratory 
procedures must be internationally standardized and evaluated in large-scale clinical 
trials to permit definition of widely accepted PCR performance parameters and have 
to be available for routine use. In order to establish a firm basis for clinical validation 
of molecular testing, there is urgent need for large prospective studies combining 
these techniques with a variety of established diagnostic tools to determine  
the potential role of PCR-based methods in the clinical management of IFD.  
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The acceptance of molecular diagnostic strategies in future consensus criteria  
for the diagnosis of IFD would significantly impact on clinical mycology.  
The inclusion of molecular testing in routine diagnostic screening would provide  
a basis for timely detection and identification of the causative fungal pathogen, 
quantification of fungal load and monitoring of the response to treatment, thereby 
leading to better management and control of IFD. In this respect, the techniques 
described in the present thesis and their implementation in an international study  
of pediatric cancer patients can be regarded as an important step towards  
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